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Inflammation is a common immunological feature of allergic diseases including 
allergic asthma and atopic dermatitis. Interactions among various types of laikocytes and 
tissue cells, such as epithelial cells and keratinocytes, through their cell surfa ce molecules 
and secreted soluble fa ctors including cytokines, are critical in orchestrating 
proinflammatory responses, which contribute to the manifestations of allergic diseases. 
Blood and tissue eosinophilia is a distinctive feature of allergic inflammation. Therefore, 
eosinophils have been one of the therapeutic targets for allergic diseases.
Eosinophils are principal effector cells involved in the late phase allergic response via 
activation by T helper type 2 (Th2) cytokines, such as IL-3, IL-5, and GM-CSF. This may 
result in changes in the expression of cell surface adhesion molecules, promoting 
transendothelial migration from vascular system into the site of inflammation  The 
activation can also induce degranulation and cytokine release from eosinophils, leading to 
exacerbation of allergic inflammation Novel IL-1 fa mily cytokine interleukin (IL)-33 has 
been shown to activate Th2 lymphocytes, mast cells, and basophils to produce an array of 
proinflammatory cytokines. Noting the fact that IL-33 can mediate blood eosinophilia, IgE 
secretion, and hypertrophy of airway epithelium in mice, the potential importance of IL-33
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in eosinophil-mediated allergic inflammation was investigated. We studied the in vitro 
effects of eosinophil activation upon stimulation of IL-33, and its structural family 
members - IL-1β and IL-18, of the IL-1 fa mily. In addition, the underlying intracellular 
signaling mechanisms regulating this activation of eosinophils were fu rther- examined.
Using flow cytometry, the expression of cell surfa ce and intracellular ST2, the 
receptor for IL-33, was detected in human eosinophils. IL-33 (at 50 ng/ml) could enhance 
eosinophil survival from 53% to 89% significantly (p < 0.05). IL-33 could also markedly 
up-regulate cell surface expression of adhesion molecule intercellular adhesion molecule 
(ICAM)-1, but suppress that of IC AM-3 and L-selectin on eosinophils in a dose-dependent 
manner (all p  < 0.05). Profile of cytokine release from eosinophils activated by IL-33 was 
first screened by protein array, followed by quantification of cytokines using enzyme-linked 
immunosorbent assay (ELISA). IL-33 could mediate proinflammatory cytokine IL-6 and 
chemokine CXCL8 and CCL2 release significantly in time- and dose-dependent maimer 
(12& 24h, 0 - 100 ng/m], all p < 0.05).
The above stimulatory effects of IL-33 on human eosinophils could be suppressed by 
specific chemical inhibitors of several intracellular signal transduction pathways including 
nuclear fa ctor kappa B (NF-kB) pathway, p38 mitogen-activated protein kinase (MAPK) 
pathway, and extracellular signal-regulated kinase (ERK) pathway (all p  < 0.05). 
Intracellular staining and quantitative flow cytometric analysis revealed the significant
n
Abstract
increase in phosphorylation of signaling molecules inhibitor kappa B (I-KBα), p38 MAPK, 
ERK in human eosinophils upon IL-33 stimulation (all p < 0.05).
The IL-1 fa mily cytokines BL-1β and IL-18 (both at 50 ng/ml) could also enhance 
eosinophil survival significantly from 46% to 86%, and from 49% to 82%, respectively (all 
p  < 0.05). Moreover, IL-1β, but not IL-18, could mark edly up-regulate cell surfa ce 
expression of adhesion molecule intercellular adhesion molecule (ICAM)-1 in a 
dose-dependent manner (p < 0.05). The profile of cytokine release from eosinophils 
activated by IL-1β and IL-18 was also screened by protein array, followed by quantification 
of cytokine concentration using ELISA. Similar to IL-33, IL-1β and IL-18 could induce 
IL-6 and chemokine CXCL8 and CCL2 release significantly in time- and dose-dependent 
manner (12  & 24 h, 0 -100 ng/ml, allp  < 0.05), via the activation o f NF-kB，p38 MAPK, 
and ERK pathways.
The synergistic effects of IL-6 production from human eosinophils mediated by the 
combined effects of IL-1β, IL-18 and IL-33 were also revealed. As both IL-lβ and IL-6 
were reported to promote differentiation o f Thl7 lymphocytes, which have been linked to 
the pathogenesis of inflammatory diseases, the synergistic increase in IL-6 pr oduction may 
induce paracrine activation of Thl7 lymphocytes to elicit more profound allergic responses. 
Noting the fact that microbial lipopolysaccharide could activate dendritic cells and 
macrophages to release IL-33, the enhanced EL-6 release induced by IL-33, as well as
m
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IL-1β and IL-18, may amplify the inflammatory responses in microbial infection, in 
addition to the exacerbation of allergic inflammation
In addition, the IL-33-mediated interaction between eosinophils and epidermal 
keratinocytes was studied. IL-33 could induce marked increase in expression of adhesion 
molecules CD18 and ICAM-1 on human eosinophils and human epidermal keratinocytes, 
respectively; as well as a further profound elevation of the expression of these adhesion 
molecules in the co-culture system (all p  < 0.05), promoting prominent direct interaction 
between eosinophils and keratinocytes at the site of inflammation. The IL-33-mediated 
secretion of pro-inflammatory cytokine IL-6 and chemokines CCL2 and CXCL8 could 
also be significantly enhanced in the co-culture system, suggesting that keratinocyte- and 
Langerhans cell-derived IL-33 may be involved in the pathogenesis of atopic dermatitis.
In conclusion, this study demonstrated the pivotal roles of IL-33 and its related IL-1 
family cytokines IL-1β and IL-18 in the immunopathogenesis of allergic inflammation via 
the activation of eosinophils, as well as the interaction between human eosinophils and 
epidermal keratinocytes mediated by IL-33. Further elucidation of the complex interaction 
between resident structural cells and eosinophils, and their underlying mechanisms should 
provide more insight for the immunological basis of allergic diseases, and facilitate the 







素 。血液和組織嗜酸性粒細胞增多是變應性炎症的一個顯著特點。因 此 ，嗜酸性粒 
細胞一直是一個治療過敏性疾病的靶標 。









IL-33及其結構家族成員- IL-1β 和IL-8 對嗜酸性粒細胞的激活作用。此外，我們 
也探索了調節嗜酸性粒細胞激活的潛在細胞内信號機。
V
應用流式細胞術，我們發現人類嗜酸性粒細胞表達細胞表面和細胞内的S T 2  
(IL-33受体）。IL-33 (5 0 毫微克/ 毫升）可顯著增強嗜酸性粒細胞存活率，從 53% 
至 89% ( p < 0.05)  。IL -33也可劑量依賴性地顯著上調細胞表面粘附分子細胞間粘 
附 分 子 (ICAM) -1的 表 達 ，但抑制的 ICAM - 3 和 L -選擇素中的表達（均 <  
0.05) 。蛋白質陣列篩選和酶聯免疫吸附試驗 (E L IS A )的量化試驗证明，白細胞 
介 素 33可時間和劑量依賴性地調節促進炎性細胞因子IL-6 和趨化因子CXCL8和 
CCL2的 釋 放 （12及 24小 時 ，0-100毫微克 / 毫 升 ，均 p < 0.05) 。
上 述 IL-33對人嗜酸性粒細胞的刺激作用可以被特定的细胞信號分子化學抑製 
劑所抑制，它們包括核因子 - k B  (NF- k B  ) 通路 , p38絲裂原活化蛋白激酶 (MAPK) 
通 路 ，細胞外信號調節蛋白激酶 (E R K )途徑的化學抑製劑（均 p < 0 .0 5 )。細胞内 
染色和流式細胞儀定量分析顯示 IL - 3 3 顯著增加人嗜酸性粒細胞中磷酸化的信號分 
子抑製劑  k B  ( Ikβα) 、p38 MAPK 和 ERK ( 均p  <  0.05 ) 。
IL-1家族的細胞因子 IL-lβ 和 IL-18 (在 50毫微克 / 毫升）可以顯著增強嗜酸性 
粒細胞存活率，分别是從46% 到 86% 和從 49% 到 82% (均p <0.05) 。此 外 ， 
IL- 1 β ’ 但不包括 IL-18 , 可劑量依賴性地顯著上調細胞間粘附分子 (ICAM) - 1 的 
表達 (p < 0 .0 5 )。蛋白質陣列篩選和酶聯免疫吸附試驗（ELISA)的量化試驗註明， 
如 IL-3 3、IL-1β 和 IL-8 能分别通過激活NF- k B ， p38 MAPK及 ERK途徑時間和 
劑量依賴性地誘導 IL-6 和趨化因子CXCL8和 CCL2的釋放(12及 24小時，0 - 100 
毫微克/毫升，均p <0.05) 。
IL-1β、 IL-18和 IL-33混合可以誘發人類嗜酸性粒細胞協同釋放IL-6 。鑒於 
IL-lβ 和 IL-6可以促進T hl7細胞分化，而T hl7細胞與炎症性疾病具有重要關聯，
協同增加分泌的 IL - 6 可旁路激活T hl7淋巴細胞 ’ 從而加重過敏性反應。因為微生 
物脂多糖能激活樹突狀細胞和巨噬細胞釋放 IL-3 3，IL-33、 IL-1β 和 IL-18 引起的 
IL-6釋放增加，不僅可以加重變應性炎症反應，也能加重微生物感染中的炎症反應。
此 外 ，我們研究了 IL-33介導的嗜酸性粒細胞和表皮角質形成細胞間的相互作 
用 。兩種细胞共培養顯示 IL -3 3 可顯著誘導人嗜酸性粒細胞粘附分子C D 1 8 表達增 
加和人表皮角質形成細胞 ICAM-1表達的增加（所有p  <  0.05 ) ，從而促進組織炎症 
中的嗜酸性粒細胞和角質形成細胞的直接聯系。共培養也可以顯著增強 IL-33介導 
的促炎性細胞因子 IL-6 和趨化因子CCL2和 CXCL8的分泌，提示我們角質形成細 
胞和郎格罕細胞分泌的 IL-33可能參與了特應性皮炎的發病。
總括而言，這項研究表明IL-33及其相關 IL-1 家族細胞因子 IL-lβ 和 IL-18可 
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Chcqyter 1 General Introduction 
Chapter 1 
General Introduction 
1.1 Allergic diseases and allergic inflammation 
1.1.1 Allergic diseases and their prevalence 
The term 'Allergy' was first proposed by Clemens von Pirquet in 1906 to describe an 
acquired, specific, altered reactivity towards allergens (Pepys, 1973). Allergens are antigens 
that trigger specific immunologic mechanisms to initiate hypersensitivity reaction, resulting 
in the development of allergic diseases, which include asthma, rhinitis, conjunctivitis, 
dermatitis, urticaria, food hypersensitivity, drug hypersensitivity, insect sdng or bite 
hypersensitivity, and an^hylaxis (Johansson et od., 2004). It is estimated that about 300 
million people worldwide currently suffer from at least one type of allergic diseases 
(Braman, 2006; Warner et al., 2006). Prevalence of aller^c diseases like asthma has been 
high in developed countries, including United Kingdom, Australia, Canada and America, 
but low in developing countries such as China (The International Study of Asthma and 
Allergies in Childhood (ISAAC) Steering Committee, 1998; Pearce et al., 2000). In 
addition, the prevalence atopic rate with symptoms of current wheeze, speech limiting 
wheeze, rhinoconjunctivitis and flexural dermatitis was significantly higher in Chinese 
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schoolchildren from Hong Kong (41.2%) than those in Beijing (23.9%) and Guangzhou 
(30.8%) (Wong et al., 2001). Anticipated increase in prevalence of allergic diseases may 
become a challenge of clinical practice and public health planning (Shea et al., 2008). 
1.1.2 Immunopathology of aDergic inflammation 
Upon allergen challenge, mast cell degranulation is first provoked in early phase 
allergic response, followed by T lymphocyte activation and eosinophil infiltration, leading 
to the development of late phase allergic inflammation (Peaiiman, 1999; Kay, 2001; 
Holgate et al, 2006). While IgE-mediated mast cell activation in early phase inflammatory 
response occurs within minutes after allergen exposure; late phase inflammatory reaction 
develops at about six to nine hours, and slowly resolves within several days (Peaiiman, 
1999; Kay, 2001). The high-affinity IgE receptors (FcsRI) on surfece membrane of mast 
cells bind IgE released from antigen-stimulated B lymphocytes. Antigen cross-linking of 
IgE bound to mast cell high-affinity IgE receptors stimulates mast cells to release 
preformed granule proteins and other mediators, including histamine, prostaglandin, and 
leukotriene; and synthesize inflammatory cytokines to activate and promote the influx of 
Th2 lymphocytes and eosinophils, which could release an array of inflammatory mediators 
and play a central role in late phase allelic response (Figure 1.1) (Peaiiman, 1999; Kay, 
2001; Holgate etal, 2006). 
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Figure 1.1. Pathophysiology of early phase and late phase allergic 
(modified from Kay, 2001) 
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1.2 Biology of human eosinophils 
1.2.1 Morphology 
Eosinophils are terminally differentiated cells derived from the bone marrow. They 
are approximately 8 ^min diameter and each of them has a bi-lobed nuclais. Eo^ophils 
are granulocytes possessing many cytoplasmic membrane-bound basic granule protdns, 
which avidly take up acidic dye eosin to give a characteristic appearance under microscope. 
In addition, eosinophils contain non-membrane bound lipid-rich inclusions, which store 
arachidonic acid, in thdr cytoplasm (Gldch et al.’ 1993; Holgate et al.’ 2006). 
1.2.2 Cell surface receptors and mediators 
Eosinophils utilize a number of surfece adhesion molecules, such as CDllb CD18 
CD49d, and CD62L, for tethering, rolling, adhesion, and transendothelial migration from 
vascular compartment into inflamed tissue (Broide et al., 2001; Wardlaw, 2001; 
Rothenbei^ et al., 2006). Cytokine receptors and immunoglobulin receptors are also 
present on eo ophils for eliciting chemotaxis, respiratory burst, and degranulation 
(Rothenbeig et al., 2006; Wines et al., 2006). In addition, eosinophils also expressed several 
types of toll-like receptors (TLR), namely TLRl, -2, -4, -5 -7 and -9, on their cell surfece 
for driving microbe-induced innate responses via activation of intracellular signaling 
mechanisms (Wong et al., 2007). Common surface markers found on eosinophils are 
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illustrated in Figure 1.2. 
Upon activation, eosinophils could secrete cytotoxic granule cationic proteins, 
including major basic protein (MBP), eosinophil cationic protein (ECP), eosinophil 
peroxidase (EPO), and eosinophil derived neurotoxin (EDM), and lipid mediator 
platelet-activating factor (PAF), leukotriene C4 (LTC4), and prostaglandin E2 (PGE2) to 
induce tissue damage and dysfiinctioa Eo^ophils could also rdease an array of cytokines 
like interleukin (IL)-2, IL-4, IL-6, and chemoldnes like CCL3, CCL5, CCLll, capable of 
promoting T lymphocyte proliferation, leukocyte activation and trafficking (Rothenberg et 
al., 2006). Eosinophil granule protdns and other mediators are summarized in Figure 1.2. 
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1.23 Origin and development of eosinophils 
Eosinophils are produced in the bone marrow from pluripotential stem cells, which 
initially differentiate into a hybrid precursor with shared properties of basophils and 
eosinophils, and then into a separate lineage of eosinophils. IL-3, IL-5, and 
granulocyte-macrophage colony-stimulatory fector (GM-CSF) are critical cytokines 
responsible for regulating e o ^ p h i l development. They promote permissive proliferation 
and differentiation of eosinophils. Under homeostatic conditions, terminally differentiated 
eosinophils migrate into thymus, mammary gland, utems, and the gastrointestinal tract 
(Rothenber^ et cd., 2006). Eosinophils eventually undergo apoptosis and are subsequently 
recognized and engulfed by macrophages (Haslett, 1997). 
1.3 Eosinophils and allergic inflammation 
Eosinophils have long been regarded as classical end-stage effector cdls involved in 
host defense (Rothenbeig et al., 2006; Rosenberg et a/. 2007). Nevertheless, recent studies 
revealed the significance of eosinophils in allergic inflammation. Tissue eosinophilia is a 
hallmark of allergic diseases. In addition, the accumulation of eosinophils in inflamed tissue 
has been correlated with severity of allei]gic diseases (Rothenberg et a/. 2006; Rosenbeig et 
al, 2007). Unlike circulating eosinophils with a short half-life of 18 hours, it has been 
suggested that activated eosinophils in inflamed tissue could survive for a longer period of 
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time, ranging from several days to several weeks (Vignola et ai, 1999; Kankaanranta et a/. 
2000; Rothenbeig et oL, 2006). 
In response to allergic provocation, trafficking of eosinophils into inflammatory sites 
involves specific interactions of surfece adhesion molecules, such as selectins and integrins, 
on eosinophils and vascular endothelium; Th2 cytokines like IL-4, IL-5, and 11^13; and 
chemokines including CCL5 and CCLll (Roteib^g et al., 2006; Rosenb^ et al., 2007). 
13.1 Adhesion molecules on eosinophils for emigration 
Eosinophil trafficking from vascular compartment into site of inflammation is a 
stepwise tethering, rolling, and firm adhesion prcx e^ss, which involves sequential 
interactions of numerous adhesion molecules expressed on both eosinophils and 
endothelium (Kitayama et al., 1997; Broide et al.’ 2001; Wardlaw, 2001; Rosenheim et al., 
2007). While initial weak interaction between selectins and glycoprotein ligands promotes 
tethering and rolling of eosinophils on endothelium, subsequent firm adhesion of 
eosinophils on endothelium is mediated by integrins and immunoglobulin superfamily 
molecules like intercellular adhesion molecules (ICAMs), facilitating diapedesis of 
eosinophils (Wardlaw, 2001; Rosenberg et al. 2007; Smith, 2008). In addition to the 
regulation of differential adhesion molecule expression, chemoattractants like CCL5 and 
COLll, as well as their receptors like CCRl and CCR3, are critical for mediating 
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eosinophil transmigration into local vascular endothelium (Figure 1.3) (Kitayama et oL 
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Figure 13. Eosinophil trafficking from vascular compartment into site of 
inflammation (modified from Rosenheim et al^ 2007) 
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1.3.1.1 Sdectin 
The sdectin femily is con^rised of three membm, namely I^selectin (CD62L), 
E-selectin (CD62E) and P-selectin (CD62P). These selectins share a unique structural 
characteristic in their extracellular r ^ o n , which contains an aminoterminal 
calcium-dependent lectin domain, an epidermal growth factor-like domain, and two to nine 
short consensus repeat units (Tedder et al., 1995). P-selectin is initially stored in granules of 
endothelial cells and platelets, and mobilized rapidly after cell activation, such as histamine 
stimulation of endothelial cell and thrombin stimulation of platelets. E-sdectin is caressed 
by endothelial cells activated by IL-lp and TNF-a. L-sdectin is constitutively expressed on 
most circulating leukocytes, including neutrophils, monocytes, and eosinophils. The 
surfece expression of L-selectin is modulated by metalloprotease-dependent shedding of 
the extracellular domain upon cell activation (Tedder et al, 1995; Smith, 2008). Selectins 
and their glycosylated mucin-like ligands present on eosinophils and the vascular 
endothelium promote initial tethering and rolling of eosinophils (Tedder et al., 1995 
Rosenberg et al., 2007; Smith, 2008). Besides direct tethering of laikocytes on the 
underlying substrates, secondary tether between previously adherent leukocytes and 
flowing leukocytes promotes further accumulation of newly adherent cells downstream of 
previously adherent cells (Kitayama et al., 1997). 
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13.1.2 Integrin 
Integrins are non-covalently linked aj3 heterodimers that are widely expressed on 
leukocytes and tissue cells. Each integrin subunit has a large extracellular domain, a single 
transmembrane domain, and a short cytoplasmic domain (Wardlaw, 2001; Smith, 2008). 
Purified human blood eosinophils express seven integrin heterodimers, namely CD49i^29, 
CDlla/18, CDllb/18 CDllc/18, CDlld/18, CD49d/29 CD49d/p7, and CD49e29 
(Barthel et al., 2008). Each type of these integrin heterodimers interacts with its 
corresponding ligands, wWch could be present in extracellular matrix or a oounter-recqjtor 
on other cells for regulating leukocyte transmigration (Rosenberg et al, 2007). Diverse 
types of ligands for CDlla/18 include intercellular adhesion molecule (ICAM)-1, ICAM-2, 
ICAM-3, ICAM-5; while those for CDllb/18 include albumin, fibrinogen, intercellular 
adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and 
vitronectin, which contribute to firm adhesion of leukocytes onto endothelium, promoting 
their accumulation at the she of inflammation (Wardlaw, 2001; Barthel et al., 2008; Smith, 
2008). 
1.3.1.3 Immunoglobulin supeifamOy 
,Immunoglobulin superfamily comprises intercellular adhesion molecule (ICAM) 
family, vascular cell adhesion molecule (VCAM)-1, and junctional adhesion molecule 
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(JAM), sharing a structure comprising 2 to 9 extracellular immunoglobulin superfemily 
domains, a hydrophobic transmembrane region, and a short cytoplasmic tail. The ICAM 
family consists of five members, namely ICAM-1, ICAM-2, ICAM-3, ICAM-4, and 
ICAM-5, which are all type I transmembrane glycoproteins. Whilst ICAMs and JAMs are 
widely expressed on leukocytes and endothelial cells; VCAM-1 is constitutively expressed 
on endothelium, eprtheliuin, fibroblasts, and smooth muscle cells. The cell surface 
expression of immunoglobulin superfamily is up-regulated upon stimulation of 
inflammatory cytokines. This superfemily is vitally involved in eosinophil trafficking as 
binding sites for integrins, such as CDlla/18, CDlld/18 CDllc/18, and CD49d/29, and 
functions as a signaling molecule, resulting in activation of inflammatory signal cascades 
(Wardlaw, 2001; Roserte^ etal, 2007; Smith, 2008). 
U.1.4 Chemokine receptors 
Chemokines are a group of small (8 to 12 kDa) protein molecules that could induce 
chemotaxis of a variety of cells, including lymphocytes, monocytes, eosinophils, and 
neutrophils (Borish et al., 2003). Chemokines signal via their specific G-protein-coupled 
seven transmembrane-spanning chemokine receptors on cell. surface of leukocytes to 
mediate their migration in response to the chemokine gradient towards the site of 
inflammatioa Various types of CXC receptors (CXCR) and CC chemokine receptors 
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(CCR) expressed on various leukocytes have been identified. For instance, monocytes 
express CC chemokine receptors CCRl, CCR2, CCR4, CCR5, and CCR9; while 
basophils express CCRl, CCR2, and CCR3 on their cell surfece. Some of these chemokine 
receptors such as CCRl and CCR2 could be selectively inducible on lymphocytes^ 
following activation by cytokines like 11^2. Noting the fact that eosinophils express CCRl 
receptors which bind CCL3, CCL5, and CCL7; and possess CCR3 receptors which bind 
CCL5, CCL7 CCL8, CCLll, and CCL13, the broad range binding affinity of chemokine 
receptors towards wide spectrum of chemokines facilitates the transmigration of 
eosinophils along a gradient of increasing chemokines at the inflamed tissue (Rothenbei^ et 
oL, 1999;Broide <2001) . 
1.3.2 Eosinophil activation and inflammatory mediators 
1.3.2.1 Cytokines and chemokines in aDergic inflammation 
Upon activation, eosinophils can produce and secrete a wide variety of cytokines such 
as IL-1 femily cytokines and IL-6, and chemokines like CCL2 and CXCL8; driving 
proinflammatory immune responses in allergic diseases like asthma and atopic dermatitis 
(Rothenberg et al,, 2006; Hogan et al.’ 2008). Cytokines are proteins with small molecular 
size, ranging from 8 to 80 kDa. Acting in an autocrine or paracrine manner, cytokines could 
potently regulate proliferation aixl differentiation, apoptosis, chemotaxis and chemokinesis, 
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adhesion of various cell types at picomolar and even femtomolar levels (Roht et al., 2001). 
Chemokines are a large femily of chemotactic cytokines that could be subdivided into four 
groups, namely CXC, CC, C, and CX3C, according to number and spacing of conserved 
N-terminal cysteine residues (Rothenberg et al., 1999; Wong et al., 2004). Similar to 
cytokines, chemokines are potent cellular activating factors that could orchestrate with wide 
variety of cytokines to activate leukocytes and endothelial cells, enhance leukocyte 
adhesion molecule interaction affinity, and induce rapid activation of signal transduction 
cascades in allergic inflammation. In addition, diemokines serve as potent chemoattractants 
that direct accumulation of leukocytes into the inflamed tissues in response to the 
chemokine gradient, contributing the pathogenesis of allei]gic inflammation (Rothenberg et 
al., 1999; Rothenberg et al., 2006). 
13.2.1.1 n^l cytokine family 
The roles of IL-1 femily cytokines, including IL-la, IL-ip, E^lRa, BL-18, and six 
novel members IL-1F5-10 and lL-33, in destructive inflammation have been investigated 
(Barksby et a/., 2007). The most studied IL-1 femily cytokines BL-ip and IL-18 are 
produced by various cell types including monocytes, macrophages, neutrophils, and 
keratinocytes (Dinarello, 1999; Arend et a/., 2008). It has been reported that IL-ip could 
induce fever, rdease of hepatic acute-phase proteins, synthesis of prosta^andin E2 
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synthesis, and cartilage breakdown in joints (Dinarello, 1994). EL-ip was also shown to 
induce polarization of Thl7 lymphocytes, which have been linked to the pathogenesis of 
inflammatory and autoimmune diseases (Acx)sta-Rodriguez et al., 2007). Moreover, lL-18 
acts as an IFNy-inducing factor in T lymphocytes and natural killer cells, and enhances 
natural killer cell cytotoxicity. Previous studies also demonstrated that IL-18 could promote 
recruitment of CD4+ T lymphocytes and neutrophils, suggesting a role of IL-18 in driving 
inflammatory responses in allergic conditions (Dinarello, 1999; Komai-Koma et a/., 2003). 
There is overwhelming evidence suggesting that the proinflammatory cytokines 
IL-lp and IL-18 could be involved in allergic inflammatioa IL~ip could promote IgG and 
IgE synthesis, Th2 cytokine production, mast cell and Th2 lymphocyte activation, as well 
as development of hypersensitivity responses in mouse model (Nakae et al, 2003; Nambu 
et al, 2006). Significant elevation of IL-lp concentration in nasal secretions of allergic 
rhinitis patients was reported (Bachert et a/., 1999). In addition to the evidence showing that 
IL-18 could stimulate allergic sensitization, airway eosinophilia, and Th2 cytokine 
production in mouse model (Kumano et al. 1999; Wild et al., 2000), plasma IL-18 
concentration was shown to be significantly higho" in allergic asthmatic patients than 
normal control subjects (Wong et a/, 2001). 
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1.3.2.1.2 VLr6 
IL-6 is synthesized by mukiple types of cells, such as T lymphocytes, B lymphocytes, 
monocytes, fibroblasts, keratinocytes and endothelial cells. IL-6 is a pleiotropic cytokine 
that could induce growth of T lymphocytes, differentiation of cytotoxic T cells and 
macrophages, formation of mukilineage blast cell colonies in hematopoiesis, and promote 
growth of epidermal keratinocytes. Previous studies revealed that IL-6 could induce fever 
and stimulate production of acute-phase proteins such as C-reactive protein (Naka et cd., 
2002; Nishimoto et al., 2006). Similar to IL-ip, TLr6 was also reported to mediate 
differentiation ofThlT lymphocytes, which the pathogenesis of several inflammatory and 
autoimmune diseases (Acosta-Rodriguez et al., 2007). Previous study demonstrated that 
alleigic asthmatic patients showed higher plasma IL-6 concentration than normal controls, 
implying its importance in allergic inflammation (Wong et al., 2001). 
13.2.13 CCL2 
CCL2 is synthesized by a variety of cells, including macrophages, lymphocytes, 
basophils, epithelial cells, endothelial cells, and fibroblasts, upon induction of diverse 
proinflammatory stimuli like IL-lp, lL-6, TNF-a and lipopolysaccharide. CCL2 is a CC 
chemokine that signals via the receptor CCR2 and mediates chemotaxis of monocytes, 
lymphocytes, and basophils. In addition to the recruitment of r^ la tory and effector 
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leukocytes, CCL2 could induce histamine and leukotriene release from both mast cells and 
basophils, as well as production of transforming growth factor-p from fibroblasts (Conti et 
oL, 1995; Rose et oL, 2003). Taken together with the clinical evidence showing 
significantly higher concentration of CCL2 in bronchoalveolar lavage fluid of asthma 
patients than that of control subjects, CCL2 might act as a critical cytokine for the 
pathogenesis of allergic inflammation (Alam et al., 1996). 
1J.Z1.4 CXCL8 
Monocytes and macrophages are the principal cellular sources of CXCL8 (Remidc, 
2005). CXCL8 is a CXC chemokine that signals via the receptor CXCRl and CXCR2 
(Rothenberg et al., 1999). CXCL8 is not only a chemoattractant of neutrophils, it could also 
potentiate neutrophil oxidative burst, resulting in tissue destruction at the site of 
inflammation (Rothenberg et al., 1999; Kobayashi et al.’ 2008). In addition, CXCL8 could 
modulate the expression of extracellular matrix protein and adhesion molecules likeCDllb 
and CD66b for promoting transmigration of leukocytes into inflamed tissue (Kobayashi et 
al., 2008). It has been reported that serum concentration of CXCL8 was significantly higher 
in severe asthmatics than that in controls, implying its potential role in mediating allergic 
responses (Silvestri et al., 2006). 
17 
Chcq)ter 1 General Introduction 
1 3 3 Survival of eosinophils in aOergic inflammation 
Delayed eosinophil apoptosis induced by activators like 11^3, IL-5, and GM-CSF is a 
central mechanism of eosinophilia responsible for prolonged survival and fiinctioning of 
eosinophils within inflamed peripheral tissues (Gleich et cd., 1993; Kankaanranta et cd., 
2000; Borish et al., 2003). Apoptosis is characterized by chromatin condensation, genomic 
DNA fragmentation caused by caspase-activated DNase, changes in mitochondrial 
membrane permeability, and translocation of phosphatidylserine from the inner leaflet to 
outer leaflet of the plasma membrane (Vignola et al., 1999; Krysko et cd., 2008). It is a 
dynamic process involved in the regulation of immune effector cells at site of inflammation. 
The number of ap to t i c eosinophils was found to be inversely correlated with the disease 
severity of allergic asthma (Vignola et al., 1999; Kankaanranta et al., 2000). 
1.3.4 Immunopathologica] roles of eosinophils in aOergic inflammation 
1.3.4.1 Eosinophils in allergic asthma 
Airway eosinophilia is a hallmark in asthma and the pathogenesis of disease. 
Following transmigration of eosinophils into the respiratory tract, further activation of 
eosinophils resuhs in secretion of various granule proteins including major basic protein, 
eosinophil cationic protein and eosinophil peroxidase; cytokines such as IL-4, IL-5, IL-13, 
GM-CSF, and TNF-a; chemokines like CCL5 and CCLll; and platelet-derived growth 
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factor. These mediators could induce damage of airway epithelial cells, stimulate mucus 
secretion and fibrosis, and mediate bronchospasm and airway hyperre^nsiveness, leading 
to the progression of allergic asthma (Cohn et al, 2004; Bochner ei a/., 2005). In addition, 
previous studies demonstrated that eosinophil numbers in the sputum and airway 
epithelium was correlated with disease severity, and eosinophils from untreated allergic 
asthmatic subjects contained significantly more intracellular eoanophil-derived neurotoxin 
when compared with eosinophils from heahhy control subjects (Cohn et al., 2004; 
Sedgwick e/a/., 2004). 
1.3.4.2 Eosinophils in atopic dermatitis 
Atopic dermatitis is characterized by q)idermal alterations and a dermal inflammatory 
infiltrate containing dendritic cells, T lymphocytes, and eosinophils, resulting in skin barrier 
dysfunction and hypeireactivity. Upon exposure to immunological stimuli such as allergens 
and microbes, dendritic cells present allergens and activate Th2 lymphocytes. Systemic 
Th2 responses inducing IgE release from B lymphocytes, proinflammatory cytokine and 
chemokine production from Th2 lymphocytes, contribute to the exacerbation of allergic 
inflammation (Incorvaia et al., 2008). In chronic atopic dermatitis, eosinophilia was found 
to be more pronounced in lesions with marked epidermal hyperplasia^ and it was correlated 
with the diseases severity. Elevated amounts of eosinophil-derived mediators, such as 
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eosinophil cationic protein, eosinophil derived neurotoxin, and major basic protdn, was 
also found in the blood and skin of atopic dermatitis patients (Simon et cd., 2004). 
1.4 Intracellular signaling mechanisms 
1.4.1 Signal transduction pathways of eosinophils 
Activation of eosinophils is initiated by binding of various mediators, including 
cytokines and chemokines, to their recqjtors for activation of downstream intracellular 
signaling pathways, leading to the development of eosinophil-mediated allergic diseases. 
With a view to understanding more about the disease processes, it is essential to investigate 
intracellular signaling mechanisms that r^ulate the activation, apoptosis, d^ranulation, 
chemotaxis, and recruitment of eosinophils to inflamed tissues. Indeed, intensive studies 
demonstrated the role of intracellular signal transduction in regulation of various biological 
functions of eosinophils, and their significance in the pathogenesis of allergic inflammation. 
Various intracellular signal transduction pathways include RAS-RAF-mitogen-activated 
protdn kinase (MAPK), Janus kinase (JAK)-signal transducer and activator of transcription 
(STAT), phosphatidylinositol 3-kiiiase (PBK), and nuclear factor-k^pa B (NF-KB) 
pathways (Figure 1.4) (Wong et oL, 2002). 
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Figure 1.4. Intracellular signal transduction pathways in human eosinophils 
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1.4.1.1 RA&-RAF-MAPK pathway 
The mitogen-activated protein kinase (MAPK) cascade is composed of a series of 
three enzymes, namely p38 MAPK, extracellular signal regulated kinase (ERK) and c-Jun 
amino terminal kinase (INK), that integrate various signals from the extracellular 
environment to regulate gene expression MAPKs are serine and threonine kinases that are 
activated by upstream MAPK kinases (MKK), which in turn are activated by MAPK 
kinase kinases (MAPKKK) (Kumar et oL, 1999; Wong etoL, 2002). While p42/44 MAPK 
(ERK) is activated by growth fectors like 11^5 for re la t ing cell proliferation, 
transformation, and differentiation; p38 MAPK is activated by osmotic stress, UV 
irradiation, as well as other environmental stresses including hyperosmolarity. Similar to 
p38 MAPK, JNK/SAPK is a protdn kinase cascade transducing cellular stress signals and 
is activated by irradiation, inflammatory cytokines, and other environmental stresses such 
as hyperosmolarity. Both p38 MAPK and JNK are involved in the regulation ofapoptosis, 
stress response, and inflammation. In activated MAPK pathways, many transcription 
factors, such as Elk-1, oJun, activating transcription factor-2 (ATF-2), and cyclic 
AMP-response element binding protean, are phosphorylated and activated, resulting in the 
gene transcription for regulating apoptosis, proliferation, differentiation, cytokine synthesis, 
and adhesion molecule expression of eosinophils (Wong et al., 2002; Wong et al., 2004). 
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1.4.1.2 JAK-STAT pathway 
JAKs are a family of cytoplasmic tyrosine kinases that are associated with cytokine 
receptors via conserved box-1 motifs and are pivotal in initiating cytokine signaling. Upon 
ligand-receptor interactions, JAKs are activated by trans-phosphorylation of two 
receptor-bound JAK molecules, followed by subsequent phosphorylation of specific 
tyrosine residues in the cytoplasmic region of the cytokine receptors. The pho^horylated 
receptors then serve as docking sites for Src homology 2 domain-containing protdns like 
cytoplasmic transcription fktor STATs. STAT molecules associate with the 
phosphorylated tyrosine sites and turn into tyrosine phosphorylated through the action of 
JAKs. Activated STATs thai dissociate from the receptors, dimerize, translocate to the 
nucleus, and interact with specific canonical DNA elements to elicit gene transcriptioa The 
JAK/STAT pathway is fundamental to a variety of biological processes^ such as apoptosis 
and chemotaxis, and is tightly regulated by several mechanisms along the signaling cascade, 
including suppressor of cytokine signaling and protein inhibitors of activated STAT. The 
implications of JAK/STAT for allergic inflammation have been postulated previously 
(Wong et aL, 2002; Wong et al., 2004; Chen et al., 2007). 
1.4.1.3 PDK pathway 
PBKs are a protein femily that is capable of catalyzing the phosphorylation of the 
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3-OH position of inositol head groups of phosphoinositide lipids, namely 
phosphatidjdinositol, phosphatidylinositol 4-pfcosphate, and phosphatidylinositol 
4^-bisphosphate. According to the structure and lipid substrate specificity ofPDKs, they 
can be categorized into three different classes, in vMch class I PDKs have been extensively 
studied Class I PI3Ks are activated by cell surfece receptors, such as growth fectors, insulin, 
and G-protem-coi5)led receptors, followed by phosphorylation of i5)stream Src-femily 
tyrosine kinase, such as Lyn. The activated PDKs phosphorylate phosphatidylinositol 
4,5-bisphosphate into phosphatidjdinositol 3,4,5-tiisphosphate, a ubiquitous second 
messenger. Phosphaddyiinositol 3,4^-trisphosphate could interact with downstream 
signaling molecules with pleckstrin homology domains, such as protein kinase B/Akt of 
protein serine/threonine kinases, and phosphoinositide-dependait kinase 1; or protein 
kinase C(PKC and PKCa) and MAPK signaling pathway. The activated Akt kinase 
phosphorylates downstream Foridiead box O (FoxO) transcription fectors, such as AFX, 
FKHR, and FKHRLl, negatively regulating their Iranscription activity (Bnmet et al” 1999; 
Kashii et ai, 2000). In addition, Akt interacts with phosphoiylated IKB kinase at Thr-23 to 
stimulate the transactivation domain of the p65 subunit of NF-kB, and associates with and 
phosphorylates transcriptional coactivator p300 at Ser-1834 for driving gene transcription 
( M ^ d et oL’ 2000; Huang et d., 2005). The importance ofPDK pathway in regulating 
multiple cellular processes, including cell growth, proliferadon, differentiation, apoptosis, 
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DNA repair, chemotaxis, and production of inflammatory mediators from the cells, has 
been reported in previous studies (Wong et cd., 2004; Ito et al., 2007). 
1.4.1.4 NF-KB pathway 
NF-KB is a protein transcription fector that drives the transcription of a variety of 
genes, including cytokines and growth fectors, adhesion molecules, immunoreceptors, and 
acute-phase proteins, essential for driving inflammatory responses. The mammalian NF-KB 
family consists ofp50 (NF-KB1), p52 (NF-KB2), p65 (RelA), Rel and RelB, which share 
an amino-terrninal Rel homology domain and are r^ulated by eight IKB femily members, 
including IkBo, Ikfip, EkBy, IkBe, IKBNS (NF-KB6), plOO, pl02 and Bd-3. NF-KB is 
sequestered in quiescent cells by interacting with the cytoplasmic inhibitors IKB-O, IKB-P, 
or IKB-E. Upon cell activation, IxBa undergoes rapid ubiquitin-mediated proteasomal 
degradation that results in the rdease of the bound, cytoplasmic NF-KB dimers. Dimers of 
NF-KB proteins composed of two Rel family proteins: p50 and RelA bind to KB sites in 
promoters or enhancers of target genes. Unlike p50, RelA contains a transactivation 
domain in the C-terminal end of the protdn, which initiates gene transcription through the 
recruitment of transcriptional co-activators and transcriptional co-repressors (Wong et al., 
2002; Wong et al., 2004; Ghosh et al., 2008). 
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1.4.2 Inhibitors of signaling molecules 
Molecular investigation of signal transduction mechanisms involved in the 
pathogenesis of allergic inflammation could enrich our understanding on the underlying 
physiologic and pathologic processes. Different from intercdiular inflammatory mediators, 
intracellular signaling molecules are less functional redundant. This enables inhibition of 
cellular activation induced by multiple cytokines and other mediators via the blockage of 
one common signaling molecule (Gorska etcd., 2003). 
An array of chemical compounds that inhibit various intracellular signal transduction 
pathways, including M A P K , JAK/STAT, P B K , and NF-KB pathways, have been 
discovered and investigated recently (Wong, 2005). For instance, pyridinylimidazole 
compound SB203580 can specifically inhibit the activity but not the phosphorylation of 
p38 MAPK (Kumar et al.’ 1999). While SP600125 is a reversible ATP-competitive 
inhibitor that spedfically blocks the phosphorylation of JNKs, such as JNKl, JNK2 and 
JNK3 (Bennett et al, 2001), U0126 is a potent and sdective MEKl/2 inhibitor that blodcs 
intracellular ERK phosphorylation (Favata et al., 1998). The tryphostin AG-490 blocks 
phosphorylation of protein tyrosine kinase in JAK/STAT pathway specifically (Meydan et 
al, 1996; Kumano et a/., 2000). LY294002 is a specific inhibitor of PBK phosphorylation 
(\%hos et al., 1994; Ito et al., 2007). BAYl 1-7082 can selectively and iireversibly inhibit 
phosphorylation oflKB-a in NF-KB pathway (Table 1.1) (Pierce ei a/., 1997). 
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Table 1.1. Inhibitors of intracellular signal transduction pathways and their 
principal mechanisms 
Inhibitor Signaling pathway Principal mechanism 
AG-490 JAK/STAT Blocks phosphorylation of JAK-2 tyrosine kinase 
BAYl 1-7082 NF-KB Selectively and irreversibly inhibits iKB-a 
phosphorylation 
LY294002 PBK Selectively blocks phosphorylation ofPBK 
SB203580 p38MAPK Specifically inhibits the activity ofp38 MAPK 
SP600125 JNK Acts as a reversible ATP-cwmpetitive inhibitor 
that specifically blodcs the phosphorylation of 
JNKl,JNK2andJNK3 
U0126 KKK Selectively inhibits MF,K-dependent ERK 
phosphorylation 
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Previous studies reported that the signaling inhibitors showed significant potential for 
abolishing a variety of pathological processes involved in allergic diseases through the 
inhibition of specific signal transduction pathways. For instance, intratracheal 
administration of PDK inhibitor LY294002 in mouse asthma models could abrogate 
antigen-induced airway eosinophilia, secretion of IL4, IL-5, 11^13, and eotaxin in 
bronchoalveolar lavage fluid, goblet cell hyperplasia, and airway hyperresponsiveness 
(Duan et oL, 2005), while ERK inhibitor U0126 could significantly reduce antigen-induced 
airway inflammatory cell infiltration, IL-4, 11^5, IL-13 and eotaxin concentration in 
bronchoalveolar lavage fluid, IgE and mucus production, VCAM-1 expression and airway 
hyperresponsiveness dose-depeiidently in a mouse asthma model (Duan eta/., 2004). 
Based on the modification of the inhibitors' chemical stmctures, there are increasingly 
more patent ^plications with preliminary clinical results reported^ providing more potential 
new therapeutic approaches in allergy (Cirillo et a/., 2002; Dominguez et al., 2005). 
Recently, the anti-inflammatory effects of specific short-intafering RNA (siRNA) or 
antisense oligonucleotides sequences targeting at post-transcriptional inhibition of gene 
expression have been investigated. Diverse inhibitory taigets may include cell surface 
receptors, adhesion molecules and ligands, ion channels, cytokines and chemokines, 
intracellular signal transduction molecules, and transcription factors involved in 
Th2-mediated allergic inflammatory responses (Popescu, 2005). siRNA application was 
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shown to be able to abolish cellular responses, release of the primary gene products such as 
cytokines, and eosinophil infiltration in mouse asthma model (Suzuki et oL, 2009). The 
development of more effective and specific signaling inhibitors may therefore facilitate 
fiindamental research and advance novel therapeutic strategies for allergic diseases (Gcffska 
etal., 2003). 
1.5 Aim of study 
Allelic asthma and atopic dermatitis are chronic inflammatory diseases with 
increasing incidence rate in Hong Kong and developed countries (The International Study 
of Asthma and Allergies in Childhood (ISAAC) Steering Committee, 1998). Recently, 
IL-33 was identified as a novel IL-1 femily cytokine produced by bronchial smooth muscle 
cells and epithelium, as well as activated dermal fibroblasts and keratinocytes upon IL-lp 
or TNF-a stimulation (Schmitz et al., 2005). 
IL-33 has been regarded as potent inducer of inflammatory T helper type 2 responses, 
eo^ophilia, and allergic inflammation (Schmitz et oL, 2005; Kondo et al., 2008; 
Kurowska-Stolarska et al., 2008). Noting the fact that eosinophils are the principal effector 
cells involved in allergic inflammation, the aim of this research study is to elucidate 
immunological mechanisms regulating the activation of IL-33 on human eosinophils, 
especially in the aspects of survival enhancement, modulation of surfece adhesion molecule 
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expression, as well as release of cytokines and chemokines, with a comparison of two other 
structurally related lL-1 femily cytokines, I H p and IL-18. 
The complex interaction between resident structural cells and eosinophils has been 
postulated as a fimdamental mechanism directing the progression of allergic inflammation 
(Wong et al., 2006). The in vitro co~culture study of eo^ophils and keratincxrytes has an 
initial objective to investigate the eosinophil-keratinocyte interaction mediated by IL-33, 
and fecilitate the accumulation of scientific information about the modulation of adhesion 
molecule expression, and stimulation of proinflammatory cytokine and chemokine 
production in this specific system, unraveling more immunopathological roles of IL-33 in 
atopic dermatitis. 
The investigation of IL-33-mediated activation of eosinophils, and the interaction 
between eosinophils and keratinocytes should provide insight for the immunological basis 
of allergic diseases, and promote the development of new therapeutic strategy for treating 
eosinophil-mediated allergic inflammation. 
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Chapter 2 
Materials and Methods 
2.1 Materials 
2.1.1 Human eosinophils 
2.1.1.1 Human Bufly Coat 
Fresh human bufiy coat was obtained from healthy volunteers via the Hong Kong Red 
Cross Blood Transfusion Service. Eosinophils were purified from bu% coat within 48 
hours after donation 
2.1.1.2 Magn^c Cell Sorting System (MACS) and Anti-CD16 Magnetic 
MicroBeads 
The MACS (Mltenyi Biotec, Bergisch dadbach, Germany) comprised three components, 
namely MdiMACS Separation Unit, MACS MuWStand, and LS Separation Column 
which could separate up to 2 x 10^  total cells and 10^  magnetically-labeled cells. The 
anti-CD 16 magnetic MicroBeads (Miltenyi Biotec, Bergisch Qadbach, Germany) were 
conjugated with monoclonal mouse anti-human CD 16 antibodies. Negative selection of 
untouched eosinophils from peripheral blood was performed by depletion of 
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CD16-positive neutrophils. 
2.1.1.3 Phosphate-Buffered Saline (PBS) solution (IX) 
PBS (IX) at 7.4 pH was prepared by dissolving PBS powder (Sigma-Aldrich, MO, USA) 
coursing of 0.2 g monobasic potas^m phosphate, 0.2 g potassium chloride, 8 g sodium 
chloride and 1.15 g dibasic sodium phosphate in 1 Liter double distilled water. The PBS 
solution was then sterilized by autodaving at \2\°C for 15 min. 
2.1.1.4 PercoU™ Solution (1.082 g/ml) 
PercoU solution (150 ml, density 1.082 g/ml) was freshly prq^ared by mixing 87.9 ml 
PercoU stock solution (density 1.130 g^ml, GE Healthcare, NJ, USA), 15 ml sterilized 1.5 
M NaCl and 47.1 ml sterilized double distilled water in cuhure hood. 
2.1.1.5 Sodium Chloride (NaQ) Solution (1.5 mol/L) 
NaCl solution (1,5 mol/L) was prepared by dissolving 87.6 g NaCl (Sigma-Aldrich, MO, 
USA) in 1 Liter double distilled water and sterilized by autodaving at 121°C for 15 min. 
The concentrated stock solution was further diluted to 1.8% (w/v) and 0.9% sterile normal 
saline. The solutions were then kept at 4 C . . 
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2.1.1.6 Wash Buffer 
Sterilized PBS solution supplemented with 2% heat-inactivated fetal bovine serum (Gibco 
Invitrogen Corporation, CA, USA) was used as wash buffer in MACS and kept at 4 C. 
2.1.2 Cell culture 
2.1.2.1 Primaiy Human Epidermal Keratinocytes 
Primary human epidermal keratinocytes (SdenCell Research Laboratories, CA, USA) 
were isolated from human normal epidermal tissue. 
2.1.2.2 Growth Medium for Human Epidermal Keratinocytes 
EpiLife Medium was purchased from Invitrogen Corporation, CA, USA. It contained 60 
\ M of calcium chloride for the growth of normal human keratinocytes. Human 
Keratinocyte Growth Supplement was also used for maintaining a complete culture 
environment for the growth of normal human qjidermal keratinocytes. It was an ionically 
balanced supplement containing bovine pituitary extract, bovine insulin, hydrocortisone, 
bovine transferrin, and human epidermal growth fector. 
2.1.2.3 Culture Medium for Human Eosmophils and Keratinocytes 
Rosewell Park Memorial Institute (RPMI) 1640 medium containing L-ghitamine and 25 
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mM hydroxyl-^yl-piperazme-N'-2-ethene-sulfonic acid (HEPES) was purchased from 
Gibco, Invitrogen Corporation, CA, USA. No antibiotic was added in all culture solutions 
and they were free of detectable endotoxin (<0.1 EU/ml). 
2.1.2.4 Serum Supplements 
Fetal bovine serum (Gibco, Invitrogen Corporation, CA, USA) was tested with low 
endotoxin (<10 EU/ml) and hemoglobin (<10 mg/ml) level. Heat-inactivated fetal bovine 
serum (HI-FBS) was prepared by heating 50 ml aliquots at 56°C for 30 min and stored at 
-20°C until use. 
2.1.2.5 Trypan Blue Solution 
Trypan blue solution (Sigma-Aldrich Co., MO, USA) contains 0.4% (w/v) trypan blue 
prepared in 0.81% sodium chloride and 0.06% dibasic potassium phosphate. 
2.1.2.6 Harleco Hemacolor Staining Solutions 
Harleco hemacolor staining solutions (EMD Chemicals Inc., Darmstadt, Germany) were 
used to stain peripheral blood eosinophils after cytospin. Hemacolor solution 1 was 
methanol for cell fixation; solution 2 was phosphate buffered eosin solution; solution 3 was 
phosphate buffered thiazine solution for nuclei detection. The solutions were protected 
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from light and stored at room temperature. 
2.1.2.7 Recombinant Human Cytokines 
Recombinant human DL-ip, IL-18, and 11^33 were purchased respectively from PeproTec 
Inc, NJ, USA; MBL, Naka-ku Nagoya, Japan; and R & D Systems Inc, MM, USA. 
2.1.2.8 Protein Synthesis Inhibitors 
Cycloheximide and actinomycin D were purchased from Sigma-Aldrich Co., MO, USA. 
2.1.2.9 Signal Transduction Pathways Inhibitors 
JAK inhibitor AG490, DcB-a phosphorylation inhibitor BAYl 1-7082, PBK inhibitor 
LY294002, ERK inhibitor U0126, p38 MAPK inhibitor SB203580, JNK inhibitor 
SP600125 were purchased from Calbiochem, Darmstadt, Germany. Double distilled water 
was used to dissolve SB203580, while dimethyl sulfoxide (DMSO) was used to dissolve 
AG490, BAYll-7082, LY294002, U0126, SP600125. The concentration of DMSO was 
keptat0.1%(v/v). 
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2.1.3 Cell surface and intracellular immunofluorescent staining 
2.1.3.1 Fluorescence-Activated CeO Sorted (FACS) Flow Sheath Fluid 
FACS Sheath Fluid (BD Biosciences, CA, USA) contained sodium chloride, disodium 
EDTA, potassium chloride, monobasic potassium phosphate, dibasic sodium phosphate, 
and anti-microbial agent as preservatives. The solution was kept at room temperature. 
2.1.3.2 FACS Staining Medium 
FACS staining medium was composed of 0.5% BSA and 0.01% sodium aade (NaNs) in 
IX PBS. It was kept in daric at 4®C and used for washing in immunofluorescent staining. 
2.1.3.3 Fixation and Permeabilization Buffers for intracellular staining 
Formaldehyde (Invitrogen Corporation, CA, USA) (36%) was used as fixation buffer, 
while methanol (Fisher Scientific, Leicestershine, UK) was used for permeabilization in 
intracellular staining. 
2.1.3.4 Monoclonal Antibodies for Immunofluorescent Staining 
2.13.4.1 Fluorescein isothiocyanate (FTTQ-conjugated mouse IgGi anti-human 
ICAM-1 (CD54) monoclonal antibody 
The antibody (Clone BBIG-Il, R & D Systems Inc, MM, USA) at concentration of 50 
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pg/ml was used with 2 |il per 5 x 10^  cells. 
2.13.4.2 FTTC-conjugated mouse IgGi anti-human ICAM-3 (CD50) monodonal 
antibody 
The antibody (Clone Cal 3.10, R & D Systems Inc, MM, USA) at concaitration of 25 
[ig/ml was used with 4 jJ per 5 x ICP ceils. 
2.13.43 FTTC-conjugated mouse IgGi anti-human L-sdectin monodonal 
antibody 
The antibody (Clone 4G8, R & D Systems Inc, MM, USA) at concentration of 25 ng/ml 
was used with 4 |il per 5 x 10^  cells. 
2.13.4.4 FTTC-conjugated mouse IgGi anti-human CD18 monodonal antibody 
The antibody (Clone 6.7 BD Biosciences, CA, USA) was used with 4 j i per 5 x 10^  cdls. 
2.13.4.5 FTTC-conjugated mouse IgGi monoclonal Ig isotype control 
The antibody (Clone 11711, R & D Systems Inc, MM, USA) at concentration of 25 n^ml 
was used with 4 pi per 5 x 10^  cells. The antibody (Clone MOPC-21, BD Biosciences, CA, 
USA) was used with 4 pi per 5 x 10^  cells. 
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2.13.4.6 Mouse IgGi anti-human phosph(>-Ii3 monoclonal antibody 
The antibody (Clone 39A1413, BD Biosciences, CA, USA) at concentration of 50 ng/ml 
was used with 8 pi per 5 x 10^  cells. 
2.13.4.7 Mouse IgGi anti-human phospho-£RKl/2 monoclonal antibody 
The antibody (Clone 20A, BD Biosciences, CA, USA) at concentration of 50 pg/ml was 
used with 8 pi per 5 x 10^  cdls. 
2.13.4.8 Mouse IgGi anti-human phospho-p38 monoclonal antibody 
The antibody (Clone 30, BD Biosciences, CA, USA) at concentration of 50 jig/ml was 
used with 8 per 5 x 10^  cells. 
2.13.4.9 Mouse IgGi monoclonal Ig isotype control 
The antibody (Clone M0PC-31C, BD Biosciences, CA, USA) at concentration of 50 
pg^ml was used with 8 {il per 5 X 10^  cdls. 
2.1.3.4.10 FTTC-conjugated goat anti-mouse IgG antibody 
The antibody (Invitrogen Corporation, CA, USA) at a dilution of 1:200 was used as 
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secondary antibody for indirect immunofluorescent staining with 100 pi per 5 x 10^  cells. 
2.U.4.11 FTTC-conjugated mouse IgGi anti-human ST2 monoclonal antibody 
The antibody (Clone 2A5, MBL, Naka-ku Nagoya, Japan) at concentration of 1 mg/ml was 
used with 30 pi pa* 5 x 10^  cells. 
2.1.3.5 Human Serum 
Human serum was obtained from Chinese healthy volunteers for bloddng step in 
immunofluorescent staining. 
2.1.4 Detection of cytokine and chemokine release 
2.1.4.1 Protein Array 
Semi-quantitative analysis of the ejq)ression profile of 79 different cytokines in culture 
supernatant of eosinophils was performed with the use of RayBio™ human cytokine array 
V (RayBiotech Inc., GA, USA). 
2.1.4.2 Enzyme-linked Immunosorbent Assay (ELISA) 
IL-6, CXCL8, and CCL2 concentration in culture supernatant of eosinophils and 
keratinocytes were analyzed by ELISA (BD Biosciences, CA, USA), with detection limits 
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of 2.2, 0.8 1.0 pg/ml for IL~6, CXCL8, and CCL2, respectively. Absoibance at 450 nm 
was read using VICTOR^ Mukilabel Counts modd 142(M)32 (PoidnElmer, MA, USA), 
and the values were adjusted with the corresponding reading at 540 i m 
2.1.5 Detection of cefl viability and apoptosis 
FITC-conjugated aimexin V apoptosis detection kit (Bender MedSystems, CA, USA) was 
used to detect cell viability and apoptosis. The kit consists of binding buffer, propidhim 
iodide, and recombinant human annexin V in solution containing 50 mM Tris, 100 mM 
NaCl, 1% BSA, 0.02% sodium azide at pH 7.4. 
2.1.6 Protein extraction 
Cell lysis buffer (BD Biosciences, CA, USA) containing 10 mM Tris-HCl (pH 7.5) 10 
mM dibasic sodium phosphate, 130 mM NaCl, 1% Triton X-100, 10 mM sodium 
pyrophosphate, and protease inhibitor cocktail (Boehringer Mannheim, Mannheim, 
Germany) was used for total protein extraction. 
2.1.7 Western blot analysis 
2.1.7.1 Antibodies 
Mouse anti-human ST2 antibody was purchased from R&D Systems, MN, USA. Sheep 
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anti-mouse Ig secondary antibody conjugated with horseradish peroxidase was purchased 
from GE Healthcare, NJ USA 
2.1.7.2 Polyvinylideiie Dffluoride (PVDF) Western Blotting Membranes 
PVDF membranes with pore size of 0.45 \m WCTC purdiased from C® Healthcare, NJ, 
USA, and stored at room temperature. 
2.1.73 Tris-Glycine Buffer 
Tris-glycine buffer lOX concentrate consisted of 0.25 M Tris-HCl, pH 7.5 and 1.92 M 
glycine in double distilled water. It was filtered by a 0.2 pm millipore filto- and stored at 
4 C. 
2.1.7.4 Tris-Glycine-Methanol Transfer Buffer 
The transfer buffer was prepared by mixing 20% methanol in IX Tris-glycine buffer and 
keptat4 C. 
2.1.7.5 Tris-BuflFered Saline Tween 20 (TBST) washing buffer 
It consisted of 10 mM Tris-HCl (pH 7.4) 150 mM sodium choloride and 0.05% (vol/vol) 
Tween 20 (Sigma-Aldrich Co., MO, USA). The solution was kept at 4°C. 
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2.1.7.6 Non-fat Milk Solutions (5%) 
Five g non-fet milk powder (San Hua Co, Hong Kong, China) was freshly dissolved in 100 
ml TBST washing buffer. The solution was used as a blocking sohitioa 
2.1.7.7 Enhanced Oiemiluminescent (ECL) Plus™ Western Blotting Detection 
Reagents 
The ECL Phis™ western blotting detection reagents were purchased from GE Healthcare, 
NJ, USA. Lumigen™ PS-3 detection reagent A is a ECL Plus substrate solution containing 
Tiis buffer vMe Lumigen™ PS-3 detection reagait B is a stodc acridan solution in 
dioxane and ethanol. Both reagents were stored at 4 C. 
2.1.7.8 ECLFflms (Hypeifilm™ ECL™) 
HypenBlm™ ECL™ (GE Healthcare, NJ, USA) was a high perfonnance 
chemihiminescence film used for Western blot analysis. 
2.1.8 Sodium dodecyi suifate-polyacrylamide gd electrophoresis (SDS-PAGE) 
2.1.8.1 Acrylamide Solution [30% (w/v)]. 
Acrylamide/Bis solution (30%) (29:1) was purchased from Bio-Rad Laboratories, CA, 
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USA. It was light-protected and stored at 4°C. 
2.1.8.2 Ammonium PersuUate (APS) Solution [10% (w/v> 
APS (Sigma-Aldrich Co, MO, USA) (0.5g) was dissolved in 5 ml double distilled water. 
The solution was kept in 500 pi aliquots at -20°C until use. 
2.1.83 Tris-HQ Buifer (pH 7.5) 
Tris base (Sigma-Aldrich Co., MO, USA) was prepared as 1 mol/L stock solution in 
DEPC-treated double distilled water. The buffer was first adjusted to pH 7.5 with HCl, and 
autoclaved at 1 2 r c for 15 min. 
2.1.8.4 Upper Buffer for Stacking Gel 
Upper buffer was prepared as 0.5 mol/L Tris-HCl (pH 6.8) and kept at 4°C. 
2.1.8.5 Lower Buffer for Separating Gel 
Lower buffer was prepared as 1.5 mol/L Tris-HCl (pH 8.8) and kept at 4°C. 
2.1.8.6 SDS Solution (10%) 
10 g SDS (Sigma-Aldrich Co., MO, USA) was dissolved in 100 ml double distilled water 
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and kept at room temperature. 
2.1.8.7 N, N, jV, N'-Tetra-methylethylenediamine (TEMED) 
TEMED (Sigma-Aldrich Co., MO, USA) was used for initiating polymerization of SDS 
polyacrylamide gel. It was kq>t at 4°C in dark. 
2.1.8.8 Tris-Oycine-SDS Electrophoresis Buffer (lOX) 
Tris-glycine-SDS electrophoresis buffer lOX concoitrate was composed of 0.25 mol/L 
Tiis-HCl (pH 7.5), 1.92 M glycine, and 1% SDS in double distilled water. It was filtered by 
0.2 pm millipore filter and stored at The concentrate was freshly diluted to IX 
working buffer solution for SDS-PAGE. 
2.1.8.9 Laemmli Sample Buffer 
Laemmli sample buffer (Bio-Rad Laboratories, CA, USA) contained 62.5 mM Tris-HCl 
(pH 6.8) 25% glycerol, 2% SDS and 0.01% bromophenol blue. Before use, 50 pi of 
2-mercaptoethanol (p-ME) was added to 950 |j1 of sample buffer for a final concentration 
of 5% p-ME, 710 mM. One part of sample was then diluted with two parts of sample 
buffer. 
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2.1.8.10 Prestained SDS-PAGE Standards 
Prestained SDS-PAC® standards (Bio-Rad Laboratories, CA, USA) contained blue-dye 
attached standard proteins including phosphorylase B (104 kDa), bovine serum albumin 
(81 kDa), ovalbumin (47.7 kDa), carbonic anhydrase (34.6 kDa), soybean trypsin inhibitor 
(28.3 kDa), and lysozyme (19.2 kDa). The standard proteins (total 625 pg) were prepared 
in 33% (v/v) glycerol, 3% SDS, 10 mM Tris (pH 7.0), 10 mM DTT, 2 mM EDTA, 0.01% 
NaNs, and stored at-20T. 
2.2 Methods 
2.2.1 Purification of human eosinophils 
Fresh human buffy coat, obtained from healthy volunteers via the Hong Kong Red Cross 
Blood Transfusion Service, was diluted 1:2 with IX PBS (Sigma-Aldrich, MO, USA) and 
centrifiiged using an isotonic Percoll sohition (density 1.082 g/ml, GE Healthcare, NJ, USA) 
at 4°C for 30 min at 1,000 g The mononuclear cells at the interface were removed, while 
the eosinophil-rich granulocyte fraction was collected and washed twice with IX PBS 
contaiimg 2% HI-FBS. The eosinophils-rich granulocytes layers were then incubated with 
anti-CD 16 magnetic MicroBeads (Miltenyi Biotec, Beigisch Gadbach, Germany) at 4°C 
for 45 min. CD16-positive neutrophils were depleted by passing through a LS Separation 
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Column (Mihenyi Biotec, Bergisch Gladbach, Germany) within a strong magnetic field. 
After this physical separation, the drop^hrough fraction contained eosinophils with a purity 
of at least 99% were assessed by double staining ofHarleco hemacolor staining solutions 
(EMD Chemicals Inc., Darmstadt, Germany). The viability of eosinophils was at least 98% 
as assessed by trypan blue exclusion assay. The isolated eo^ophils were cukured in RPMI 
1640 medium (Gibco, Invitrogen Corporation, CA, USA), supplemented with 10% 
HI-FBS (Gibco, Invitrogen Corporation, CA, USA). 
2.2.2 Cell culture 
2.2.2.1 Human Epidermal Keratinocyte CeD Culture 
Human epidermal keratinocytes were maintained in EpflLife Medium (Invitrogen 
Corporation, CA, USA) with Human Keratinocyte Growth Supplement (Invitrogen 
Corporation, CA, USA). The cells were incubated at 37^0 in a 95% humidified incubator 
with the supply of 5% carbon dioxide (CO2) and subcuhured on every 7-days. 
2.2.2.2 Co-culture of Human Eosinophils with Human Epidermal Keratinocytes 
Human epidermal keratinocytes were cultured in a 24-well culture plate until confluence (1 
X 10^  cells). The medium was replaced with RPMI 1640 medium (Gibco, Invitrogen 
Corporation, CA, USA) containing 10% HI-FBS (Gibco, Invitrogen Corporation, CA, 
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USA) with or without eosinophils (5 x 10^  cells). For inhibitor study, human epidermal 
keratinocytes were pre4reated with intracellular signaling molecule inhibitors for 1 h. 
1223 Study of CeU Morphology 
Cytocentrifiige preparation was commonly used to examine the morphological changes of 
cells after treatment. Eosinophils (5 x 10 , were centrifiiged at 300 rpm for 3 min on 
microscopic slide by the Shandon Cytospin Centrifuge (Cometa Scientific, Nottingham, 
UK). The cells were air-dried, stained with Harleco hemacolor staining sohitions (EMD 
Chemicals Inc., Darmstadt, Germany), and examined using Nikon Edipse E800 
microscope (Nikon Corp, Tokyo, Japan). 
2.23 CeU surface and intracellular immunofluorescent staining 
Human eosinophils and epidermal kerationocytes (5 x 10^  cells), after prior treatments, 
were washed and resuspended with cold PBS supplemented with 0.5% BSA. The cdls 
were blocked with 2% human pooled serum at 4 C for 20 min, and washed with PBS 
supplemented with 0.5% BSA. For direct immunofluorescent staining, the cdls were 
incubated either with FITC-cx)njugated mouse anti-human monoclonal antibody or 
FTTC-conjugated mouse IgGi isotype at 4®C in dark for 45 min. For indirect 
immunofluorescent staining, the cells were first incubated with either mouse anti-human 
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monoclonal antibody or mouse IgGi isotype at 4°C for 45 min, following by incubation 
FITC-conjugated anti-mouse secondary antibody (1:200) at 4°C in dark for further 30 min. 
The cells were then washed and re-suspended in 1% paraformaldehyde in IX PBS as 
fixative. For study of intracellular protein expression, eosinophils were fixed with 4% 
formaldehyde at 37°C for 10 min. After centrifugation, the cells were permeabilized in 
absolute methanol on ice for 30 min, and followed by either direct or indirect 
immunofhiorescent staining. Expression of cell surfece maiicers, adhesion molecules, and 
intracellular protdns of 10,000 viable cells was analyzed by flow cytometry 
(FACSCalibur™, BD Biosciences, CA, USA) in terms of mean fluorescence intensity 
(MFI). 
2.2.4 Detection of cytokine and chemokine release 
2.2.4.1 Protein array analysis of cytokines and chemoldnes in culture supernatant of 
eosinophils 
After 48 h incubation, the repression profile of 79 different cytokines in culture supernatant 
of eosinophils was assessed semi-quantitatively using antibody based RayBio™ human 
cytokine array V (RayBiotech Inc., CA, USA). The cytokine array map was listed in 
Appendix. . 
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2.2.4.2 Quantitative analysis of human IL-6, CXCL8 and CCL2 
Concentrations of proinflammatory cytokines IL-6, and chemokines CXCL8 and CCL2 in 
culture supernatant were quantified by ELISAkhs from BD Biosciences, CA, USA. 
2.2.5 Detection of cefl viabOity and apoptosis 
Eosinophil survival was assessed by FTTC-conjugated annexin V apoptosis detection lot 
(Bender MedSystems, CA, USA) u g flow cytometiy (FACSCalibur, BD Biosciences, 
CA, USA). 5x 10^  eosinophils after treatments were washed and resuspended in cold PBS 
supplemented with 0.5% BSA. The cells were then incubated with FTTC-conjugated 
aimexin V and propidhim iodide (PI) in dark at room temperature for 15 min. Samples 
were analyzed within 0.5 h by flow cytometry, with gating of eosinophil population based 
on its forward and side light scatter, and with exclusion of any cell dd^ris. Cell viability is 
expressed as percentage of total cells that characterized by low MFI of both FTTC-annexin 
V and PI. 
2.2.6 Protein extraction 
Eosinophils (1 x 10? cells) were washed twice with IX PBS and lysed in 150 jl cell lysis 
buffer (BD Biosciences, CA, USA) with protease inhibitor cocktail (Boduinger Mannheim, 
Mannheim, Germany). Cell debris was first removed by centrifugation at 10,000 g for 10 
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min and supernatant was boiled at lOO C^ for 5 min. Total protdns were stored as aliquots at 
-80°C until use. Protean concentrations were determined using Bradford reagent (Bio-Rad 
Laboratories Inc., CA, USA). 
2.2.7 Western blot analysis 
Equal amount of protdns (15 jog) were subjected to SDS-PAGE and separated protdns 
were blotted onto a PVDF membrane ( f f i Healthcare, NJ, USA). The membrane was then 
blocked with 5% skim milk in TBST washing buffer for overnight at 4 C, and probed with 
primary mouse antibodies against human ST2 and primary rabbit antibodies against human 
glyceraldehyde-3-phosphate dehydrogenase for 1 h at room temperature. After washing, 
membranes were incubated with secondary antibody, either sheep anti-mouse or gpat 
anti-rabbit IgQ which was conjugated with horseradish peroxide (GE Healthcare, NJ, USA) 
for 1 h at room temperature. After washing, the antibody-antigen complexes were detected 
by ECL Phis™ detection kit (GE Healthcare, NJ, USA) accoixling to the manufacturer's 
instructions. 
2.2.8 SDS-PAGE 
A Bio-Rad Mini-PROTEAN apparatus was used for discontinuous polyacrylamide gel 
electrophoresis. Lower separating gel solution was first casted into the vertical gel glass 
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plates of sizes [Inner: 7.3 x 10.2 xO.lcm; Outer: 8.3 x 10.2 x 0.1 cm (H x W x D)]. A layer 
of 0.1% SDS was laid on the top to assist the formation of a straight line interphase. After 
setting the separating gel, 5% polyacrylamide stacking gel was set with a comb to form ten 
wells [Size: 1.5 x 0.5 x 0.1 cm (H x W x D)]. Electrophore^ was carried out using 
Tris-Glycine-SDS Running Buffer at a constant voltage of 100 V for about 100 min After 
electrophoresis, the gel was either used for immunoblotting or stained with Coomassie blue 
brilliant dye (0.2% R250 Coomassie brilliant blue, 50% methanol, 10% acetic acid) for 1 h 
and de-stained with a solution of 5% methanol and 10% acetic acid. 
2.2.9 Statistical analysis 
All data were expressed as mean SEM Differences between groups were assessed by 
one way ANOVA analysis. A probability (p) < 0.05 was considered significantly different. 
All analysis was performed using the Statistical software GraphPad Prism (GraphPad 
Software, Inc, San Diego, CA, USA). 
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Chapter 3 
Role of Novel DL-l Family Cytokine 
in Allergic Inflammation: 
IL-33-mediated Eosinophil Activation 
3.1 Introduction 
IL-33 has been recently discovered as the eleventh member oflL-1 family that includes 
IL-ip and IL-18 (Schmitz et al., 2005; Baiksby et oL’ 2007). It is a novel Th2 
proinflammatory cytokine, which is abundantly expressed in human smooth muscle cells 
and bronchial epithelial cells (Schmitz et al., 2005). Administration of IL-33 in mice not 
only could initiate production of IgE and Th2 cytokines IL-5 and IL-13, but also induce 
pathological changes including blood and bronchoalveolar lavage fluid eosinophilia, 
airway hyperresponsiveness, epithelial cell hyperplasia and hypertrophy (Schmitz et al.’ 
2005; Kondo et al., 2008; Kurowska-Stolarska et al., 2008). 
Sakashita et al. (2008) reported that significant higher serum IL-33 concentration was 
found in the patients with Japanese cedar pollinosis, v^en compared with healthy control 
subjects. In addition, IL-33 has been shown to promote maturation and survival of human 
mast cells, and induce their secretion of cytokines IL-5 and IL-13 that promote survival and 
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effector functions of eosinophils (AUakhverdi et al, 2007; likura et oL’ 2008). Taken 
together with the results obtained from mouse model, IL-33 might play a pivotal role in 
exacerbation of allergic inflammation in allergic diseases mediated by eosinophils. 
It was shown previously that IL-33 could signal via its receptor ST2 with the activation 
of downstream signaling molecules including inhibitor k^pa B (I-icBa) and 
mitogen-activated protein kinases (MAPKs), and abrogation of IL-33-induced IL-5 and 
IL-l3 production from CD4+ T lymphocytes could be resulted by blocking NF-KB and 
MAPKs pathways (Schmitz et oL, 2005; Kunowska-Stolarska et a/. 2008; 
Pecaric-Petkovic et al., 2009). In addition to the evidence of enhanced NF-KB activity in 
peripheral blood mononuclear cells of asthmatic patients as reported by Gagliaido et al. 
(2003), our previous studies also demonstrated that NF-KB signal transduction, p38 MAPK 
and ERK pathways played pivotal role in regulating IL-3, IL-5, and GM-CSF-induced 
ICAM-1 expression, and Thl7 cytokines-elicited cytokine production fix)m human 
eosinophils (Wong et al., 2003; Cheung et d” 2008). 
In attempt to further investigate the activation of eosinophils induced by IL-33, we 
elucidated the intracellular signaling mechanisms regulating survival, adhesion, cytokine 
and chemokine release from eosinophils activated by IL-33, with a comparison of the 
effects of two other IL-l family cytokines, IL-l p and IL-l 8. 
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3.2 Results 
32,1 Total protein expression of IL-33 receptor, ST2, of human eosinophils 
From Figure 3.1 eosinophils and T lymphocytes constitutively expressed IL33 receptor, 
ST2, at protein level; vsMe neutrophils, keratinocyte cell line HaCaT, and mast cell line 
HMC-1 did not show any constitutive protein expression of ST2. 
60 kDa) 
Eosinophils Neutrophils HaCaT HMC-1 T lymphocytes 
Negative controls Positive control 
Figure 3.1. Representative Western blot of IL"33 receptor, ST2, protein expression 
in human eosinophils, neutrophils, HaCaT, HMC-1, and T lymphocytes 
Total proteins were extracted from eosinophils, neutrophils, HaCaT cells, HMC-1 cells, and 
T lymphocytes (1 x 10^  cells). Samples with equal protein amount (15 pg) were analyzed 
using Western blot Experiments were performed in triplicate with essentially identical 
results and representative figure is shown. 
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322 Intracellular protein expression of IL-33 receptor, ST2, in human eosinophils 
As shown in Figure 3.2, intracellular staining of eosinophils showed a low but detectable 
expression of IL-33 receptor, ST2. 
Figure 32, Representative of intracellular IL-33 receptor, ST2, protein 
human eosinophils 
Intracellular expression of IL-33 receptor, ST2, in fixed human eosinophils (5 x 10^  cells) 
was determined by flow cytometry. Blue line and red line represent isotypic control and 
medium control, respectively. Results are expressed as histograms of relative cell counts 
with fluorescence intensity. Experiments were performed in triplicate with essentially 
identical results and representative figure is shown. 
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3 2 3 Extracellular protein expression of IL-33 receptor, ST2, on human eosinophils 
As shown in Figure 3.3’ extracellular staining of eosinophils showed a low but detectable 
surface expression of IL-33 receptor, ST2, after treatment with IL-33 (50 ng/ml) for 16h. 
Figure 33. Representative of extracellular IL-33 receptor, ST2, protein expression 
on human eosinophils 
Eosinophils (5 x 10^  cells) were treated with or without IL-33 (50 ng/ml) for 16 h. Surfece 
expression of IL-33 receptor, ST2, on eosinophils was determined by flow cytometry. Blue 
line, red line, and purple line represent isotypic control, medium control, and treatment with 
IL-33 (50 ng/ml), respectively. Results are expressed as histograms of relative cell counts 
with fluorescence intensity. Experiments were performed in triplicate with essentially 
id^tical results and representative figure is shown. 
56 
Chapter 3 Role of Novel IL-l family cytokine in Eosinophil Activation 
32.4 Effects of IL-ip, BL-IS, and IL-33 on survival of human eosinophils 
Prominent enhancement of eosinophil survival was found in treatment with IL-ip IL-18, 
and IL-33, vviien compared with medium control (Figure 3.4A - M). After incubation with 
IL-ip, IL-18, and IL-33 (10 to 100 ng/ml) for 48 h, percentage of viable cells increased 
significantly, from 53.1% to 89.4% (Figure 3.4N), from 46.4% to 85.5% (Figure 3.40), and 
from 48.7% to 82.0% (Figure 3.4P), respectively. In addition, IL-18 could enhance the 
survival of eosinophils in a dose-dependent manner. 
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Figure 3.4. Effects oflL-ip, IL-18, and IL-33 on the viability of human eosinophils 
Eosinophils (5 x 10^  cells) were (A) untreated, (B - E) treated with IL-ip at 10 20 50 100 
ng/ml, (F -1) treated with IL-18 at 10 20 50,100 ng/ml, (J _ M) treated with IL-33 at 10 
20 50,100 ng/ml, for 48 h. Flow cytometric analysis was perfonned by gating eosinophils 
based on their forward and side light scatter. Viable cell population was characterized by 
low MFI of both FITC-annexin V and PI (lower left quadrant), vMe apoptotic cell 
population represented by high MFI of FITC-annexin V but low MFI of PI (lower right 
quadrant), and dead cell population was shown by high MFI of both FITC-amiexin V and 
PI (upper right quadrant). Experiments were performed in triplicate with essentially 
identical results and representative figure is shown. 
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Figure 3.4. Effects of IL-ip, IL-18, and IL-33 on the viability of human eosinophils 
(con't) 
Figure N O, P represent differences in viability of eosinophils after treatment with IL-lp, 
IL-18, and IL-33, respectively. Viable cell population was quantified as percentage of total 
gated cells and are expressed as arithmetic mean SEM of three independent experiments. 
*p< 0.05, ** p < 0.01 when compared with medium control. 
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32.5 Effects of IL-lp, IL~18 and EL-33 on surface adhesion molecule expression on 
human eosinophils 
As shown in Figure 3.5 - 3.7, IL-33 could markedly up-regulate the expression ofICAM-1 
in a dose-dependent manner, but significantly suppress ICAM-3 and L-selectin expression 
on human eosinophils. While IL-1 P could stimulate a significant increase in the expression 
of ICAM-1, but not ICAM-3 and L-selectin expression, on eosinophils; IL-18 could not 
elicit significant modulation of ICAM-1, ICAM-3, and L-selectin expression on 
eosinophils. 
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Figure 35. Effects of (A) IL-ip, (B) IL-18, and (Q IL-33 on surface expression of 
ICAM-1 on human eosinophils 
Eosinophils (5 x 10^  cells) were cultured with or without IL-ip, IL-18, and IL-33 (10 • 100 
ng/ml) for 16 h. Surface expression of adhesion molecules on 10,000 cells was analyzed by 
flow cytometiy as MFI, v ^ c h was normalized by subtracting appropriate isotypic control 
and shown as arithmetic mean SEM of three independent experiments. 




* * * * I I - * * 






















* * * 
25 50 75 
IL-33 (ng/ml) 
125 
Figure 3.6. Effects of (A) IL-lp, (B) IL-18, and (Q IL-33 on surface expression of 
ICAM-3 on human eosinophils 
Eosinophils (5 x 10^  cells) were cultured with or without IL-ip, IL-18, and IL-33 (10 -100 
ng/ml) for 16 h. Surface expression of adhesion molecules on 10,000 cells was analyzed by 
flow cytometry as MFI, which was normalized by subtracting appropriate isotypic control 
and shown as arithmetic mean SEM of three independent experiments. 
' p < 0.05, **p< 0.01, ***p< 0.001 vyiien compared with medium control. 
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Figure 3.7. Effects of (A) IL-ip, (B) IL-18, and (C) IL-33 on surface expression of 
L-selectin on human eosinophils 
Eosinophils (5 x 10^  cells) were cultured with or without IL-ip, IL-18, and IL-33 (10 _ 100 
ng/ml) for 16 h. Surfece expression of adhesion molecules on 10,000 cells was analyzed by 
flow cytometry as MFI, \\4iich was normalized by subtracting appropriate isotypic control 
arid shown as arithmetic mean SEM of three independent experiments. 
:p < 0.05 **p< 0.01 when compared with medium control. 
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32.6 Effects of IL-lp, BL-18, and IL-33 on chemokme and cytokine release from 
human eosinophils 
Figure 3.8 illustrates the cytokine expression profiles of human eosinophils using 
antibody-based human cytokine protein array as a means of preliminary screening. IL-ip, 
IL-18, and IL-33 could activate eosinophils to prominently induce the release of 
chemokines CCL2 (3e) and CXCL8 (2j), and proinflammatory cytokine IL-6 (2h) among 
the 79 different cytokines being screened after 48 h incubation \\dien compared with that of 
medium control. The configuration of the antibodies on the cytokine array membrane is 
listed in Appendix. 
Quantitative analysis of CCL2 and CXCL8, IL-6 release from eosinophils iqx)n IL-lp, 
IL-18, and IL-33 stimulation was followed. As shown in Figure 3.9 - 3.11 EL-lp, IL-18, 
and IL-33 could activate eosinophils to release CCL2 and CXCL8, IL-6 in a 
dose-dependent manner. While IL-ip, EL-18, and IL-33 could mediate comparable 
induction of CCL2 release, IL-33 elicited the strongest stimulation of CXCL8 and IL-6 
release among the three IL-1 family cytokines. 
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Figure 3.8. Representative expression profile of qtokine release from IL-ip, IL-18, 
and IL-33-treated human eosinophils 
Eosinophils (1.5 x 10^  cells) were cultured with or without IL-ip, IL-18, and IL-33 (50 
ng/ml) for 48 h. Cell-free culture supernatant was collected and 79 different cytokines in the 
supernatant were semiquantitated using antibody-based RayBio human cytokine array V. 
Positive and negative controls were designated as (la, lb, Ic, Id, 8j, 8k) and (le, If 8i) 
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Figure 3.9. Effects of (A) BL-ip, (B) IL-18, and ( Q IL-33 on CCL2 release fiT>m 
human eosinophils 
Eosinophils (1 x 10^  cells) w^e cultured with or without IL-ip, IL-18, and IL-33 (50 ng/ml) 
for 12 and 24 h. Cell-free culture supernatant was collected and CCL2 released into the 
siqjematant was quantified using EUSA. Results are expressed as arithmetic mean SEM 
of three independent experiments. 
*p< 0.05, **/?< 0.01 compared with medium control. 
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Figure 3.10. Effects of (A) IL-ip, (B) and (Q IL-33 on CXCL8 release from 
human eosinophils 
Eosinophils (1 x 10^  cells) were cultured with or without IL-ip, IL-18, and IL-33 (50 ng/ml) 
for 12 and 24 h. Cell-free culture supernatant was collected and CXCL8 released into the 
siq)ematant was quantified using ELISA. Results are expressed as arithmetic mean SEM 
of three independent experiments. 
:p < 0.05 **p< 0.01 wte i compared with medium control. 
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Figure 3.11. Effects of (A) IL-ip, (B) IL-18, and (C) IL-33 on IL-6 release fiwn 
human eosinophik 
Eosinophils (1 x 10^  cells) were cultured with or without IL-1 p, IL-18, and IL-33 (50 ng/ml) 
for 12 and 24 h. Cell-free culture supernatant was collected and IL-6 released into the 
siqjematant was quantified using ELISA. Results are expressed as arithmetic mean SEM 
of three independent experiments. . 
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3*2.7 Synergistic effects of ELrlp, ILrl8, and IL-33 on EL-^  release from human 
eosinophils 
Figure 3.12 illustrates that combined treatment of I M p (10 ng/ml) and IL-33 (10 ng/ml) 
resulted in significant synergistic increase in proinflammatory cytokine IL-6 release, while 
only additive effects were resulted for combined treatment of E L - l p (10 ng/ml) and IL-18 
(10 ng/ml); as well as that of IL-18 (10 ng/ml) and IL-33 (10 ng/ml). Synergistic effects in 
IL-6 release could be fiirther enhanced when concentration of IL-33 was double (20 ng/ml) 
in combination with fixed IL-lp concaitration (10 ng/ml). In addition, syna:gistic increase 
in IL-6 production from human eosinophils was resulted for combined treatment of IL-1 p 
(10 ng/ml) and IL-18 (20 ng/ml); as well as that ofIL-18 (10 ng/ml) and IL-33 (20 ng/ml). 
Thus, the synergistic effects of the above combinations of DL-lp, IL-18, and IL-33 were 
demonstrated in this co-stimulation study. 
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Figure 3.12. l^ergistic 
human eosinophils 
of IL-ip, IL-18, and IL-33 on IL-6 from 
Eosinophils (1 x 10^  cells) were cultured with different concentrations of IL-1 p, IL-18, and 
IL-33 in combination for 24 h. Cell-free culture siqDematant was collected and IL-6 
released into the supernatant was quantified using ELISA. Results are expressed as 
arithmetic mean SEM of three independent experiments. 
< 0.01 when compared with medium control (Ctrl). #p< 0.05, Mp< 0.01 when 
compared with sum of IL-6 production in treatment with individual cytokines (IL-33, 
IL-IP, or IL-18) added alone. 
lp(10): tt^lp (10 ng/ml); lp(20):E^lp (20 ng/ml); 18(10): IL-18 (10 ng/ml); 18(20): 
IL-18 (20 n^ml); 33(10): IL-33 (10 ng/ml); 33(20): IL-33 (20 ng/ml). 
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32.8 Effects of transcription and translation inhibitors on IL-lp, IL-18, and 
ILr33-mduced chemokine and cytokine release from human eosinophils 
As shown in Figure 3.13 to 3.15, chemokine CCL2, CXCL8 and inflammatory cytokine 
IL-6 release induced by IL-lp, IL-18 and IL-33 could be significantly siqjpressed by 
transcriptional inhibitor actinomycin D and translational inhibitor cycloheximide, 
suggesting IL-ip, IL-18 and IL-33 could induce the release of newly synthesized CCL2, 
CXCL8, and IL-6, rather than prefoimed chemokines and cytokines from eosinophils. 
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Figure 3.13. Effects of actinomycin D and cycloheximide on (A) BL-ip, (B) IL-18, 
and (€) IL-33-mduced CCL2 release from human eosinophils 
Eosinophils (1 x 10^  cells) were cultured with or without IL-ip, IL-18, and IL-33 (50 ng/ml) 
in the presence of actinomycin D (1 pM) and cycloheximide (10 \M) for 24 h. Cell-free 
culture sipematant was collected and CCL2 released into the siqDematant was quantified 
using ELISA. Results are expressed as arithmetic mean SEM of three independent 
experiments. 
###/?< 0.001 wiien compared with medium control (Ctrl); **• p < 0.001 \ \ to i compared 
with IL-lp, IL-18, and IL-33 alone; ActD: actinomycin D; Cyclo: cycloheximide. 
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Figure 3.14. Effects of actmomycin D and cycloheximide on (A) Dvlp, (B) IL-18, 
and ( Q IL-33-mduced CXCL8 release from human eosinophils 
Eosinophils (1 x 10^  cells) were cultured with or without IL-lp,lL-18,and IL-33 (50 ng/ml) 
in the presence of actinomycin D (1 nM) and cycloheximide (10 pM) for 24 h. Cell-free 
culture siq)ematant was collected and CXCL8 released into the supernatant was quantified 
using ELISA. Results are expressed as arithmetic mean SEM of three independent 
experiments. 
###p < 0.001 v^en compared with medium control (Ctrl); *** p < 0.001 when conpared 
with BL-lp, IL-18, and IL-33 alone; ActD: actinomycin D; Cyclo: cycloheximide. 
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Figure 3.15. Effects of actmomycm D and (ydoheximkle on (A) IL-ip, (B) IL-18, 
and (Q ILr33-mduced IL^ rdease from human eosinophils 
Eosinophils (1 x 10^  cells) were cultured with or without IL-lp, IL-18, and IL-33 (50 ng/ml) 
in the presence of actinomycin D (1 ^M) and cycloheximide (10 |iM) for 24 h. Cell-free 
culture supernatant was collected and IL-6 released into the siqjematant was quantified 
using ELISA. Results are expressed as arithmetic mean SEM of three independent 
experiments. Mp< 0.01 ###p< 0.001 >\iien compared with medium control (Ctrl); *p< 
0.05 **p< 0.01, *** p < 0.001 when con^)ared with IL-lp, IL-18, and IL-33 alone; ActD: 
actinomycin D; Cyclo: cycloheximide. 
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3 9 Effects of different inhibitors on IL-ip, IL-18, and IL-33-mduced survival 
enhancement of human eosinophils 
Figure 3.16 shows that pre-treatment with IKB kinase inhibitor BAYl 1-7082, ERK 
inhibitor U0126, and p38 MAPK inhibitor SB203580 for 30 min could significantly 
abolish both IL-1 P-and IL-18-induced survival enhancement of human eosinophils, vMq 
pre-treatment with BAYl 1-7082 and U0126 for 30 min could also markedly abolish 
IL-33-induced survival enhancement of human eosinophils (all p < 0.05). No significant 
difference of cell viability was found between medium control (Ctrl), and different 
signaling inhibitors namely AG490 (3 _ BAYl 1-7082 (1 _ LY294002 (5 _ 
U0126 (10 pM), SB203580 (7.5 pM), SP600125 (3 \M) alone treatment groiq)s. 
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Fgure 3.16. Effects of 6 different inhibitors on (A) BL-lp, (B) IL-18, and (Q 
IL-33-mduced survival enhancement of human eosinophils 
Eosinophils (5 x 10^  cells) were pretreated with inhibitors for 30 min followed by 
incubation with or without IL-ip, IL-18, and IL-33 (50 ng/ml) in the presence of inhibitors 
for further 48 h. Viable cell population was quantified as percentage of total gated cells and 
are expressed as arithmetic mean !SEM of three independent experiments. 
* p< 0.05, **/?< 0.01 vytoi compared between groups denoted by the horizontal lines; 
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Chapter 3 Role of Novel IL-l family cytokine in Eosinophil Activation 
32.10 Effects of different inhibitors on BL-ip, and IL-33-mediated surface 
expression of adhesion molecules on human eosinophils 
As shown in Figure 3.17 A-B, pre-treatment with IKB kinase inhibitor BAYl 1-7082, ERK 
inhibitor U0126, and p38 MAPK inhibitor SB203580 for 30 min could significantly 
abolish IL~lp, and IL-33-induced ICAM-1 expression on human eosinophils (allp< 0.05). 
Figure 3.17 C - D illustrate marked siq)pression of IL-33-induced ICAM-3 expression on 
human eosinophils after pre-treatment of U0126 and SB203580 for 30 min, as well as 
significant inhibition ofL-selectin expression on human eosinophils after pie-treatment of 
BAYl 1-7082 U0126, and SB203580 for 30min(aUp< 0.05). 
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Figure 3.17. Effects of 6 different inhibitors on (A) IL-ip, and (B _ D) ILr33-mduced 
adhesion molecule expression on human eosinophils 
Eosinophils (5 x 10^  cells) were p:etreated with inhibitors for 30 min followed by 
incubation with or without IL-lp, and IL-33 (50 ng/ml) in the presence of inhibitors for 
further 16 h (A& B) ICAM-1, (C) ICAM-3, (D) L-selectin expression on 10,000 cells was 
analyzed by flow cytometry as MFI, which was normalized by subtracting propriate 
isotypic control and shown as arithmetic mean SEM of three independent experiments. 
* p< 0.05 ** p< 0.01 *** p < 0.001 when compared between groiq)s denoted by the 
horizontal lines; AG: AG490, BAY: BAYll-7082, LY: LY294002, U: U0126, SB: 
SB203580,SP:SP600125. 
78 
Chapter 3 Role of Novel IL-l family cytokine in Eosinophil Activation 
3^.11 
CCL2, CXCL8, and EL-6 from human eosinophils 
Figure 3.18 shows that pre-tneatment with IKB kinase inhibitor BAYl 1-7082, ERK 
inhibitor U0126, and p38 MAPK inhibitor SB203580 for 30 min could significantly 
abolish IL-lp-induced CCL2 release, vMe pre-treataient with BAYll-7082, PDK 
inhibitor LY294002, and U0126 for 30 min could markedly sq>press IL-lg-induced CCL2 
release; pre-treatment with BAYll-7082 and U0126 for 30 min could significantly inhibit 
IL-33-indiiced CCL2 release from human eosinophils, (all/? < 0.05). 
In addition. Figure 3.19 illustrates that pre-trealment with BAYll-7082, U0126, and 
SB203580 for 30 min could significantly abolish IL-18and IL-33-induced CXCL8 release, 
while pre-treatment with U0126 for 30 min could also maikedly suppress IL-ip-induced 
CXCL8 release from human eosinophils (all/? < 0.05). Fmlhermore, Figure 3.20 shows 
Hiat pre-treataient with BAYll-7082, U0126, and SB203580 for 30 min could significantly 
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Figure 3.18. Effects of 6 different inhibitors on (A) IL-lp, (B) 11^18, and ( Q 
IL-33-induced CCL2 release from human eosinophils 
Eosinophils (5 x 10^  cells) were pretreated with inhibitors for 45 min followed by 
incubation with or without IL-ip, IL-18, and IL-33 (50 ng/ml) in the presence of inhibitors 
for further 24 h. Cell-free culture siqjematant was collected and CCL2 released into the 
supernatant was quantified using ELISA. Results are expressed as arithmetic mean SEM 
of three independent experiments. 
p < 0.05, ** p< 0.01 ,***/?< 0.001 vviien compared between groiqjs denoted by the 
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Figure 3.19. Effects of 6 different inhibitors on (A) IL-ip, (B) IL-18, and (Q 
IL-33-mduced CXCL8 release from human eosinophils 
Eosinophils (5 x 10^  cells) were pretreated with inhibitors for 45 min followed by 
incubation with or without IL-lp, IL-18, and IL-33 (50 ng/ml) in the presence of inhibitors 
for fiirther 24 h. Cell-free culture supernatant was collected and CXCL8 released into the 
siq)ematant was quantified using ELISA. Results are expressed as arithmetic mean ISBM 
of three independent experiments. 
p < 0.05 ** p < 0.01 . *** p < 0.001 v^en compared between groiq)s denoted by the 
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Figure 320. Effects of 6 different inhibitors on (A) n^lp, (B) IL-18, and ( Q 
EL-33-induced DL-6 release from human eosinophils 
Eosinophils (5 x 10^  cells) were pretreated with inhibitors for 45 min followed by 
incubation with or without IL-lp, IL-18, and IL-33 (50 ng/ml) in the presence of inhibitor 
for further 24 h. Cell-free culture supernatant was collected and IL-6 released into the 
supernatant was quantified using ELISA. Results are expressed as arithmetic mean ISEIM 
of three independent experiments. 
*/?< 0.05, * * p < 0.01 , ***p< 0.001 vytoi compared between groiqjs denoted by the 
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32,12 Effects of IL-33, EL-ip and IL-18 on activation of ERK, p38 MAPK, and 
NF-KB pathways in human eosinophils 
Intracellular fluorescence staining and flow cytometry were used for measuring the 
contents of phosphorylated ERK, p38 MAPK, and IKB-Q in penneabilized eosinoiMs. As 
shown in Figure 3.21A - C, ERK, p38 MAPK, and InB-a in eosinophils were rapidly 
activated vqxm stimulation of IL-lp, IL-18, and IL-33 for 15 min. In addition, 
phosphorylation of ERK, p38 MAPK, InB-a in eosinophils could be differentially induced 
iqx)n IL-lp, IL-18, and IL-33 stimulatioa 
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Figure 321. Activation of (A) ERK, (B) p38 MAPK, ( Q NF-KB in human 
eosinophils upon IL-ip, IL-18, and IL-33 stimulation 
Eosinophils (5x10^ cells) were cultured with or without IL-ip, IL-18, and IL-33 (50 ng/ml) 
for 15 min. After fixation and pertneabilization, the intracellular contents ofphosphoiylated 
(A) ERK, (B) p38 MAPK, (C) M - a in 10,000 permeabilized eosinqMs were measured 
by intracellular staining by flow cytometry. Results were normalized by subtracting 
appropriate isotypic control and shown as arithmetic mean ISEM of three independent 
experiments. 
‘p < 0.05 **/7<0.01 v^tei compared with medium control (Ctrl). 
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33 Discussion 
IL-33 has been postulated as a novel regulator of immune system by initiating 
maturation, migration, and activation of various types of leukocytes (Figure 3.22), 
including human Th2 lymphocytes (Komai-Koma et d” 2007; Smithgall et al. 2008), 
mast cells (Allakhverdi et al., 2007), basophils (Pecaric-Petkovic et oL’ 2009; Smithgal et 
al” 2008; Suzukawa et al” 2008), natural killer cells (SmithgsU et al.’ 2008), and 
eosinophils (Cherry et oL, 2008; Pecaric-Petkovic et oL, 2009; Suzukawa et al” 2008). 
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Figure 322. Multi-functional roles ofIL-33 on various types of leukocytes 
In addition, IL-lp was recently identified as a potent mediator that initiates 
differentiation ofThl? lymphocytes to drive autoimmune responses (Acosta-Rodriguez et 
oL, 2007), vMe IL-18 was widely known as an inducer that stimulates IFN- 7 production 
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from T lymphocytes and natural killer cells to promote Thl responses (Dinarello et al.’ 
1999). Intriguingly, it has been reported that both IL-lp and lL-18 could also activate 
human eosinophils (Whitcomb et al, 1989; Wang et al.’ 2001), implying possible roles of 
EL-ip and IL-18 in allelic inflammation. 
Indeed, how IL-33 and the two olher IL-1 femily cytokines IL-lp and IL-18 could 
orchestrate and promote allelic inflammatory responses is still poorly understood Noting 
the feet that IL-lp, IL-18, and IL-33 share protein sequence homology (Schmitz et al., 
2005), receptor unit, and ToU-like/tt.-1 -receptor structure in the intracellular receptor 
domain (Arend et al. 2008), the intracellular signaling mechanisms of BL-lp, IL-18, and 
IL-33 on the activation of biological fimctions of human eosinophils, in the aspects of 
modulation of adhesion molecule expression, survival enhancement, and stimulation of 
cytokine and chemokine release, were investigated 
Activation of eosinophils could be first regulated at the ligand/receptor binding level. 
We found that the expression ofIL-33 receptor, ST2, on human eosinophils was barely low, 
as concurred with previous studies (Cherry et al” 2008; Suzukawa et al.’ 2008). As soluble 
ST2 was shown to attenuate eosinophil infiltration and Th2 cytokine production in 
asthmatic murine model (Oshikawa et oL, 2002; Hayaka^ et al’ 2007), the significant 
increase in the release of soluble ST2 in viral infection (Becerra et al., 2008) and asthmatic 
exaceibadon (Oshikawa et oL, 2001) may help amplify the negative regulatory effects of 
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soluble ST2 in these disease conditions. Utilizing antagonistic effects of anti-ST2 and 
recombinant ST2 proteins in clinical plications may fecilitate the development of new 
ther^jeutic strategies for allergic diseases. 
Delayed eosinophil ptosis is a central mechanism of eosinophilia in allergic 
inflammatDiy responses (Vignola et al.’ 1999; Kankaanranta et d” 2000). Our results 
illustrated that IL-33, as well as IL-lp and IL-18, could markedly enhance the survival of 
eosinophils (Figure 3.4) suggesting that EL-lp, IL-18, and IL-33 could promote 
eosinophilia at the site of allergic inflammation. 
In addition, intravascular trafficking of eosinophils into inflammatory tissue not only 
could be driven by the interactions between eosinophil and endothelial adhesion molecules, 
the diapedesis of eosinophils could also be promoted by the interactions between 
eosinophils and extracellular matrix (Broide et d., 2001). IL-lp was previously shown to 
promote transendothelial emigration of eosinophils (Ebisawa et oL, 1992). Indeed, 
enhanced ICAM-1 expression in bronchial asthma attacks was reported previously 
(Kobayashi et al. 1994). Our results showed that both IL-33 and DL-ip could significantly 
iq>regulate cell surfece expression of ICAM-1 on human eosinophils in a dose-dependent 
maimer (Figure 3.5). Noting the fibronectin and hyaluronan-binding characteristic of 
ICAM-1 (Moser et oL, 1992; McCourt et cd” 1994), our results provide additional 
biochemical basis on IL-33-enhanced eosinophil adhesiveness to extraceullar matrix 
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components (Suzukawa et al, 2008). In addition, ICAM-1/CD18 interaction could initiate 
eosinophil firm adhesion on bronchial epithelial cells (Bmke-Gaffiiey et a!” 1998), the 
significant up-regulalion ofICAM-1 expression induced by IL-33 and IL-lp may promote 
eosinophil aggregation at the site ofinflammatioa 
Among the tested IL-1 family cytokines, only IL-33 could markedly siq)press cell 
surfece ICAM-3 expression (Figure 3.6). ICAM-3 was highly expressed on the surfece of 
human eosinophils at resting stage. The anti-inflammatoiy functions of ICAM-3 in 
inhibiting GM-CSF synthesis and inducing apoptosis of eosinophils have been suggested 
(Kessel et al’ 2003; Kessel et oL, 2006). The switching to "enhanced ICAM-1 and reduced 
ICAM-3" expression on activated eosinophils upon IL-33 stimulation may fevour the 
initiation of proinflammatoiy responses. 
Furthermore, IL-33 was the only tested IL-1 femily cytokine that could markedly 
siq)press cell surfece expression of I^selectin (Figure 3.7). I^selectin was reported as an 
adhesion molecule accounting for the initial tethering and rolling of eosinqjhils on 
endothelial cells (Kitayama et oL, 1997). Our results are in agreement with previous 
evidence revealing down-regulation of surfece exfMession of L-selectin on activated 
eosinophils after allergen challenge in asthmatic conditions (Mengelers et ai’ 1994). 
Therefore, it is hypothesized that the potent effects of IL-33 in modulating ICAM-1, 
ICAM-3, and L-selectin expression on eosinophils may help the firm adhesion of 
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eosinophils and promote their transendothelial migration to the inflamed tissues. 
Previous studies have provided overwhelming evidence to support the critical roles of 
proinflammatory cytokines and chemokines released during allergic inflammation 
(Bittleman et al.’ 1994; Minray et al” 2006). Aberrant increase in proinflammatory 
cytokine and chemokine secretion in allergic asthmatic patients was reported in clinical 
studies (Wong et al” 2001; TiUie-Leblond et al” 2000). Further to the screening of 79 
different cytokine and chemokine release from human eosinophils after IL-lp, IL-18, and 
IL-33 stimulation, Ihe selective and marked induction of CC chemokine CCL2, CXC 
chemokine CXCL8, and IL-6 release from eosinophils was quantified (Figure 3.9 - 3.11). 
Moreover, IL-lp, IL-18, and IL-33 were shown to stimulate the release of newly 
synthesized CCL2, CXCL8 and IL-6, instead of preformed chemokines and cytokines 
from eosinophils (Figure 3.13- 3.15). 
It has been reported that CCL2 concentration in bronchoalveolar lavage fluid was 
found to be elevated in allergic asthmatic patients (Alam et al, 1996). In addition, CCL2 
could initiate leukocyte infiltration and inflammatory responses by inducing chemotaxis of 
monocytes, T lymphocytes, natural killer cells, and basophils; as well as degranulation and 
histamine release from both basophils and mast cells (Conii et oL, 1995; Rose et a/. 2003). 
The expression of CCR2 receptor on human eosinophils was reported previously 
(Dunzendorfer et oL’ 2001). Taken together with the evidence demonstrating IL-33 as a 
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chemoattractant of Th2 lymphocytes (Komai-Koma et oL, 2007), the significant CCL2 
release fiom eosinophils upon IL-ip, IL-18, and IL-33 activation may facilitate both 
eosinophil and other leukocyte locomotion to promote the development of allergic 
inflammation. 
Prior study has revealed that enhanced IL-6 and CXCL8 release in body fluid could be 
resulted from allergen challenge in atopic patients (Ferreira, 2003). The neutrophil 
chemoattractant CXCL8 was shown not only to enhance surfece adhesion molecule 
expression on neutrophils to facilitate their migration and accumulation in the tissue of 
inflammation, it was also found to stimulate neutrophils to secrete granular proteins and 
produce superoxide (Kobayashi et d” 2008). Although IL-33 could not activate neutrophils 
(Cherry et oL 2008), our results suggested lhat IL-33 may orchestrate with IL-lp and IL-18 
to recruit neutrophils into the inflamed tissues. 
The central role of IL-6 in host defense and acute inflammadon was well delineated in 
previous studies (Jones, 2005). It has been suggested that Toll-like receptor ligands derived 
from microbial organisms could activate eosinophils (Wong et al.’ 2007), implying a role of 
eosinophils in linking microbial infection and allergic inflammatioa Noting the feet that 
lipopolysaccharide could also activate dendritic cells and macroj^iages to release IL-33 
(Schmitz et oL’ 2005), the enhanced IL-6 production induced by IL-33, as well as IL-ip 
and IL-18, may amplify the inflammatoiy responses in microbial infection, in addition to 
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the exacerbation of allergic inflammation (Figure 3.23). Furthermore, both IL-lp and IL-6 
were reported to promote differentiation of Thl7 lymphocytes (Acosta-Rodriguez et oL 
2007). This new subset of lymphocytes was recently discovered and characterized by its 
distinct IL-17A and IL-17F production, which may help promote leukocyte recruitmoit 
and inflammatory process in allergy (Schmidt-Weber et al” 2007). Our study on the 
activation of eosinophils induced by IL-17A and IL-17F shed light on new roles of Thl7 
lymphocytes in allergic inflammation (Cheung et d” 2008). The synergistic effects of IL"6 
production mediated by the combined effects of IL-lp and IL-18, DL-ip and IL-33, as well 
as DL-18 and IL-33, could amplify the Thl7 polarization with a paracrine loop mechanism. 
and elicit more profound effects in allergic inflammation (Figure 3.23). 
Possible role of Th l7 lymphocytes 
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Figure IL-1 family cytokines could orchestrate and induce synergistic 
in ILr6 release for amplifying inflammatory responses in microbial and 
Thl7 lymphocyte differentiation in allergic inflammation 
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Indeed, eosinophil activation was first initiated by cell surfece interaction of receptors 
and soluble ligands, followed by activation of various signaling pathways regulating 
transcription of proinflammatory genes (Wong et al. 2002). The receptors for IL-ip, IL-18, 
and IL-33 all belong to the IL-1 receptor/Toll-like receptor si5)erfamily, sharing the 
Toll-EL-l receptor unit in their intracellular domain for signaling (O'Neill, 2008). The 
significant role of Toll-IL-1 receptor domain in inflammation and host defence has been 
suggested (O'Neill et al. 2000). Our previous investigation confiimed the involvement of 
NF-KB and MAPK signal transduction pathways in Toll-like receptor-mediated eosiiK){M 
activation, suggesting their importance in linking microbial infection with allergic 
inflammation (Wong et al.’ 2007). 
With a view to elucidating Hie underlying mechanisms responsible for IL-33-mduced 
activation of eosinophils, the involvement of intracellular signaling pathways were studied 
Specific chemical inhibitors AG490, BAYl 1-7082, LY294002, U0126, SB203580, and 
SP600125 were used to investigate the intracellular signal transduction pathways regulating 
cell survival, surface adhesion molecule expression, as well as chemokine and cytokine 
release fiom eosinophils. Based on the study of loss of membrane phospholipid asymmetry 
and enhance permeability in apoptotic cells (Figure 3.16), we confirmed that the signaling 
inhibitors did not exhibit any significant cell toxicity effects on eosinophils. This is in line 
with our previous study on the cytotoxicity assay of signaling inhibitors (Wong et al.’ 
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2005). 
Given that IL-ip, IL-18, and IL-33 could all activate eosinophils and induce same array 
of cytokines and chemokines, we postulated that these IL-1 femily cytokines may share 
and transmit overlapping signal transduction pathways. The IL-lp, IL-18, and 
IL-33-induced effects in eosinophil survival could be blocked by NF-KB inhibitor 
BAYl 1-7082, ERK inhibitor U0126, and p38 MAPK inhibitor SB203580. Our present 
studies indicate the roles of and NF-KB, ERK, and p38 MAPK pathways in regulating the 
IL-1 family cytokines IL-ip, IL-18, and IL-33-mediated survival of eosinophils; surface 
adhesion molecule expression; as well as cytokine and chemokine release from eosinophils. 
Noting the fact that NF-KB could regulate the transcription of proinflammatoiy genes 
encoding cytokines and adhesion molecules, and initiate chronic inflammation, the critical 
role of NF-KB in pathogenesis of asthma has been suggested in previous studies (Makarov, 
2000; Wong et d., 2004). In addition, mounting evidence revealed that ERK and p38 
MAPK cascades could regulate proliferation, differentiation, cytokine production, 
chemotaxis and ptosis of various inflammatory cells, including Th2 lymphocytes, mast 
cells and eosinophils (Wong et d” 2004; Duan et oL, 2006). Therefore, the activation of 
NF-KB, ERK and p38 MAPK pathways in EL-ip, IL-18, and IL-33-indiiced eosinophil 
activation further confirmed the importance of these signal transduction pathways in the 
pathogenesis of allergic inflammation. 
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In conclusion, this is a coirqjrehensive report on the activation of eosinophils induced 
by BL-lp, IL-18, and IL-33 in the aspects of survival enhancanent, modulation of surfece 
adhesion molecule expression, as well as stimulation of cytokine and chemokine release, 
via the activation of NF-KB ERK and p38 MAPK pathways. Our study also unraveled the 
synergistic effects of combining BL-ip and IL-18, IL-lp and IL-33, as well as IL-18 and 
IL-33 on induction ofIL-6 release. Taken together with jHevious reports, the significance of 
this study inevitably lines in how IL-33 and its related IL-1 femily cytokines IL-lp and 
IL-18 could be involved in the pathogenesis of allergic inflammation, such as paracrine 
activation of Thl7 lymphocytes. Further investigation of the underlying mechanisms of 
eosinophil activation may provide more clues for the develojMnent of novel therapeutic 
strategies for eosinophil-associated allergic diseases. 
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Chapter 4 
Co-culture of Eosinophils & Epidermal Keratinocytes 
Upon IL-33 Stimulation: 
Implications for Immunopathology of 
Atopic Dermatitis 
4.1 Introduction 
IL-33 is abundantly expressed in dermal fibroblasts and keratinocytes iqx)n the 
activation of proinflammatoiy cytokines IL-ip and TNF-a (Schmitz et al., 2005). Unlike 
hematopoietic cells utilizing the distal promoter for initiating gene expression of IL-33 
receptor ST2, dermal fibroblasts and keratinocytes utilize proximal promoter for ST2 
transcription. Noting the selective expression of ST2 on activated Th2 lymphocytes, but not 
on Thl lymphocytes (Lecart et oL, 2002), its ligand IL-33 is postulated to have potential 
roles in mediating Th2 allergic diseases like atopic dermatitis (AD) and allelic asthma. It 
has been reported that suprabasal layers of keratinocytes exhibit significant soluble ST2 
expression in acute stage of atopic dermatitis (Shimizu er al., 2005). AD is a chronic 
relapsing skin inflammatoiy disease characterized by dispersed eczematous skin lesions 
with lichenification, pruritic excoriations, severely dry skin, dermal infiltration of 
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proinflammatoiy cells including neutrophils and eosinophils, and a susceptibility to 
cutaneous infection (Akdis et oL, 2000; Simon et oL, 2004). 
Furthermore, tissue eosinophilia can be found in both acute and chronic stages of AD 
and it was shown to correlate with the disease severity (Simon et d., 2004). In addition to 
elevated serum concentrations of eosinophil-derived major basic protein (MBP), 
eosinophil-derived neurotoxin (EDN), and eosinophil cationic protein (ECP) in atopic 
dermatitis patients, significant extracellular deposition of eosinophil granule protein in the 
upper dermis and lesions of AD skin was found, implying that activated eosinophils may 
play a major role in mediating allergic inflammation and tissue destruction in AD (Kapp, 
1993; Ott et al., 1994; Kiehl et oL, 2001). 
Keratinocytes are the principal cell population in epidermis and can be activated to 
release broad array of cytokines and chemokines (Kanitakis, 2002). Prior study 
demonstrated elevated expression of a novel keratinocyte-derived cytokine thymic stromal 
lymphopoietin in lesional epidermis of AD, possibly driving dendritic cell-mediated 
allergic inflammation (Soumelis et oL, 2002). It has been reported that the production of 
eosinophil chemoattractant CCL5 from epidermal keratinocytes could be enhanced upon 
stimulation oflFN-^ and TNF-a, favouring the recruitment of eosinophils into lesional AD 
skin tissue (Li et cd., 1996; Yamada et oL, 1997). In addition, clinical evidence revealed that 
keratinocytes from AD patients produce elevated amount of CCL2, CCL5, CCLll, and 
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GM-CSF, and other proinflammatory cytokines, promoting the proliferation and survival of 
keratinocytes, eosinophils, T lymphocytes, monocytes and dendritic cells (Yawalkar et al., 
1999; Giustizieri etoL, 2001; Pastore etoL, 2006). 
In attempt to further investigate the IL-33-mediated interaction between eosinophils 
and epidermal keratinocytes, we studied the in vitro effects of IL-33 in cx)-culture of 
eosinophils and epidermal keratinocytes, with a preliminary focus on the aspects of surface 
adhesion molecule expression, as well as cytokine and chemokine release in the co-culture 
system. 
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4.2 Results 
42.1 Effect of IL-33 on surface expression of CD18 and ICAM-1 upon tiie 
interaction of human eosinophils and epidermal keratinocytes 
Figure 4.1 shows that IL-33 could significantly augment the expression of CDl 8 on human 
eosinophils. In addition, CD 18 expression on human eosinophils and ICAM-1 expression 
on human epidermal keratinocytes were significantly enhanced vvtoi they were cultured 
together. Furthermore, IL-33 could markedly up-regulate the expression of CD 18 and 
ICAM-1 in the co-culture system. 
42.2 Effect of IL-33 on CCL2 release upon the interaction of human eosinophils 
and epidermal keratinocytes 
As shown in Figure 4.2, IL-33 could significantly induce the release of CCL2 fix)m 
eosinophils. The production of CCL2 was markedly enhanced when eosinophils and 
epidermal keratinocytes were cultured together. Upon IL-33 stimulation, the induction of 
CCL2 production was further augmented significantly in the co-culture system. 
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(A) (B) 
• Without IL-33 
E D With IL-33 (50 ng/ml) 
15. 
X 
Eosinophils only Eosinophils 
in co-culture 
• Without IL-33 
• With IL-33 {50ng/ml) 
Keratinocytes only Keratinocytes 
in co-ci 
Figure 4.1. Effect of IL-33 on surface expression of (A) CD18 and (B) ICAM-1 upon 
the interaction of human eosinophils and epidermal keratinocytes 
Eosinophils (5 x 10^  cells) and confluent epidermal keratinocytes (1 x 10^  cells) were 
cultured either together or separately with or without IL-33 (50 ng/ml) for 16 h. Surfece 
expression of (A) CD 18 and (B) ICAM-1 on 10,000 cells was analyzed by flow cytometry 
as MFI, which was normalized by subtracting propriate isotypic control and shown as 
arithmetic mean SEM of three independent experiments. 
p < 0.05 < 0.01, *** p < 0.001 when compared between groiq)s denoted by the 
horizontal lines. 
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Figure 42, Effect of IL-33 on CCL2 release upon the interaction of human 
eosinophils and epidermal keratmocytes 
Eosinophils (5 x 10^  cells) and confluent epidermal keratinocytes (1 x 10^  cells) were 
cultured either together or separately with or without IL-33 (50 ng/ml) for 24 h. Cell-fi^ 
culture supernatant was collected and CCL2 released into the supernatant was quantified 
using ELISA. Results are expressed as arithmetic mean SEM of three independent 
experiments. 
E: Eosinophils; K: Keratinocytes 
*p< 0.05 ***/?< 0.001 when compared between groups denoted by the horizontal lines. 
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4 J 3 Effect of IL-33 on CXCL8 release upon the interaction of human eosinophils 
and epidermal keratinocytes 
Figure 4.3 shows that IL-33 could significantly induce the release of CXCL8 from both 
eosinophils and epidermal keratinocytes. The production of CXCL8 was markedly 
enhanced v^en eosinophils and epidermal keratinocytes were cultured together. Upon 
IL-33 stimulation, the induction of CXCL8 production was further augmented significantly 
in the co-culture system. 
42.4 
epidermal keratinoqtes 
As shown in Figure 4.4 IL-33 could significantly induce the release of IL-6 fix)m botii 
eosinophils and epidermal keratinocytes. The production of IL-6 was markedly enhanced 
when eosinophils and epidermal keratinocytes were cultured together. Upon IL-33 
stimulation, the induction of IL-6 production was finther augmented significantly in the 
co-culture system. 
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Figure 43. Effect of IL-33 on CXCL8 upon the of human 
eosinophils and epidermal keratinocytes 
Eosinophils (5 x 10^  cells) and confluent epidermal keratinocytes (1 x 10^  cells) were 
cultured either together or separately with or without IL-33 (50 ng/ml) for 24 h, Cel l - fe 
culture supernatant was collected and CXCL8 released into the siqjematant was quantified 
using ELISA. Results are expressed as arithmetic mean SEM of three independent 
experiments. 
E: Eosinophils; K: Keratinocytes 
‘p < 0.05, **•/?< 0.001 when compared between groups denoted by the horizontal lines. 
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Figure 4.4. Effect of IL-33 on IL-6 upon the of human 
eosinophils and epidermal keratinocytes 
Eosinophils (5 x 10^  cells) and confluent epidermal keratinocytes (1 x 10^  cells) were 
cultured eilher together or separately with or without IL-33 (50 ng/ml) for 24 h. Cell-fee 
culture siqDematant was collected and JL-6 released into the siq)ematant was quantified 
using ELISA. Results are expressed as arithmetic mean SEIM of three independent 
experiments. 
E: Eosinophils; K: Keratinocytes 
p < 0.05, **/? < 0.01 *** p < 0.001.\\toi compared between groiq)s denoted by the 
horizontal lines. 
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4 2 3 Source(s) of CCL2 in co-culture of eosinophils and epidermal 
keratinocytes upon IL-33 stimulation 
For investigating the source(s) of cytokines and chemokines released in the co-culture 
system, the secretion of cytokines and chemokines released from either eosinophils or 
epidermal keradnocytes in the co-culture system were blocked by fixing the cells with 1% 
paraformaldehyde, while preserving the cell membrane for direct interaction between 
eosinophils and epidermal keratinocytes via their surface adhesion molecules (Lai et oL 
1988) (Figure 4.5). 
Fixation of eosinophils ” Direct interaction between eosinophils & keratinocytes 
Eosinophil 
Keratinocyte 
ICAM-1 i C X 
2) Cytokine & chemokine release from eosinophils^^ 
3) Cytokine & chemokine release from keratinocytes 
Fixation of keratinocytes 




2) Cytokine & chemokine release from eosinophils 
3) Cytokine & chemokine release from keratinocytes^^ 
Figure 45. Effects of fixation on the direct interaction between human eosinophils 
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42S Source(s) of CCL2 in co-culture of human eosinophils and epidermal 
keratinocytes upon BL-33 stimulation (con't) 
Figure 4.6 shows that the co-culture of fixed eosinophils and unfixed epidermal 
keratinocytes, as well as fixed epidermal keratinocytes and unfixed eosinophils totally 
abrogated the secretion of cytokines and chemokines in co-culture with or without IL-33 
stimulation, suggesting both eosinophils and epidermal keratinocytes are the sources of 
CCL2 in the co-culture system. 
42.6 Source(s) of CXCL8 in co-culture of human eosinophils and epidermal 
keratinocytes upon IL-33 stimulation 
As shown in Figure 4.7, the co-culture of fixed eosinophils and unfixed epidermal 
keratinocytes, as well as fixed epidermal keratinocytes and unfixed eosinophils markedly 
abolished the release of cytokines and chemokines in co-culture with or without IL-33 
stimulation, suggesting both eosinophils and epidermal keratinocytes are the sources of 
CXCL8 in the co-culture system. 
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Figure 4.6. Source(s) of CCL2 in co-culture of human eosinophils and epidermal 
keratinocytes upon IL-33 stimulation 
Eosinophils (5 x 10^  cells) and confluent epidermal keratinocytes (1 x 10^  cells) were 
treated with or without 1% paraformaldehyde for 1 h on ice prior to culture together with or 
without IL-33 (50 ng/ml) for 24 h. Cell-free culture supernatant was collected and CCL2 
released into the supernatant was quantified using ELISA. Results are expressed as 
arithmetic mean SEM of three independent experiments. 
E: Eosinophils; E^: Fixed eosinophils; K: Keratinocytes; K^: Fixed keratinocytes 
*/?< 0.05, ***p< 0.001 wiien compared between groups denoted by the horizontal lines. 
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Figure 4.7. Source(s) of CXCL8 in co-culture of human eosinophils and epidermal 
keratinocytes upon IL-33 stimulation 
Eosinophils (5 x 10^  cells) and confluent epidermal keratinocytes (1 x 10^  cells) were 
treated with or without 1% paraformaldehyde for 1 h on ice prior to culture together with or 
without IL-33 (50 ng/ml) for 24 h. Cell-free culture supernatant was collected and CXCL8 
released into the siq)ematant was quantified using ELISA. Results are expressed as 
arithmetic mean SEM of three independent experiments. 
E: Eosinophils; E^: Fixed eosinophils; K: Keratinocytes; K^: Fixed keratinocytes 
0.05, ***p< 0.001 compared between groups denoted by the horizontal lines. 
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42.1 Source(s) of IL-6 in co-culture of human eosinophil and epidermal 
keratinocytes upon IL-33 stimulation 
Figure 4.8 shows that the co-culture of fixed eosinophils and unfixed epidermal 
keratinocytes, as well as fixed epidermal keratinocytes and unfixed eosinophils 
significantly reduced the secretion of cytokines and chemokines in co-culture with or 
without IL-33 stimulation, suggesting both eosinophils and epidermal keratinocytes are the 
sources ofIL-6 in the co-culture system. 
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Figure 4.8. Source(s) of IL-6 in co-culture of human eosinophils and epidermal 
keratinocytes upon IL-33 stimulation 
Eosinophils (5 x 10^  cells) and confluent epidermal keratinocytes (1 x 10^  cells) were 
treated with or without 1% paraformaldehyde for 1 h on ice prior to culture together with or 
without IL-33 (50 ng/ml) for 24 h. Cell-free culture supernatant was collected and IL-6 
released into the supernatant was quantified using ELISA. Results are expressed as 
arithmetic mean SEM of three independent experiments. 
E: Eosinophils; E^: Fixed eosinophils; K: Keratinocytes; K^: Fixed keratinocytes 
*p< 0.05, *** p < 0.001 v^en compared between groiq)s denoted by the horizontal lines. 
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4.2.8 Effect of transwell insert on the induction of CCL2, CXCL8, and IL-6 release 
in co-culture of human eosinophils and epidermal keratinocytes upon ILr33 
stimulation 
In attempt to examine v^ether direct interaction was essential for induction of CCL2, 
CXCL8, and IL-6 release in the co-culture of eosinophils and epidermal keratinocytes upon 
IL-33 stimulation, transwell insert with pore size of 0.4 pm was used to separate 
eosinophils and keratinocytes into two compartments in the co-culture system. Intercellular 
communication through soluble mediators, such as cytokines and chemokines, was 




1) Direct interaction between eosinophils 
keratinocytes 
Eosinophil 
Keratinocyte ~ ~ 
CD18 
ICAM-
2) Cytokine & chemokine release from both 
eosinophils & keratinocytes 
Figure 4.9. Effects of transwell insert on the direct interaction between human 
eosinophils and epidermal keratinocytes and their cytokine production in the 
co-culture system 
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4.2.8 Effect oftranswell insert on the induction ofCCL2, CXCL8, and IL-6 release 
in co-culture of human eosinophils and epidermal keratinocytes upon IL-33 
stimulation (con't) 
As shown in Figure 4.10, it seems that the presence of transwell insert could reduce the 
IL-33-mediated release of CCL2 in co-culture of IL-33 treated eosinophils and 
keratinocytes, though it is not statistically significant {p = 0.0636). Without IL-33 
stimulation, induction of CCL2 release in co-culture was also significantly abolished in the 
presence of transwell insert, suggesting that CCL2 release in the co-culture system may 
depend on direct interaction between eosinophils and epidermal keratinocytes. In addition, 
the release of CXCL8 and IL-6 in co-culture of IL-33 treated eosinophils and keratinocytes 
could not be blocked by the transwell inserts, suggesting that soluble mediators may be 
used for intercellular communication and induction of cytokine and chemokine release. 
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Figure 4.10. Effect of transweU insert on the induction of (A) CCL2, (B) CXCL8, 
and ( Q IL-6 release in co-culture of eosinophils and epidermal keratinocytes upon 
IL-33 stimulation 
Eosinophils (5 x 10^  cells) and confluent epidermal keratinocytes (1 x 10^  cells) were were 
cultured together with or without IL-33 (50 ng/ml) in the presence or absence of transwell 
insert for 24 h. Cell-free culture siq^ematant was collected and (A) CCL2, (B) CXCL8, and 
(C) IL-6 released into the siq)ematant was quantified using ELISA. Results are expressed 
as arithmetic mean SEM of three independent experiments. 
* p< 0.05, ** p< 0.01 *** p < 0.001 when compared between groups denoted by the 
horizontal lines. 
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43 Discussion 
IL-33 is inducible in keratinocytes iqx)n stimulation of proinflammatoiy IL-1 family 
cytokine IL-1 P (Schmitz et al” 2005). It has been reported that keratinocytes highly express 
IL-33 receptor ST2 in acute stage of atopic dermatitis (Shimizu et a/. 2005). In Chapter 3 
we reported that IL-33, as well as two other IL-1 family cytokines IL-lp and IL-18, could 
activate eosinophils and induce significant enhancement in cell survival, changes in surface 
adhesion molecule expression, as well as cytokine and chemokine release. It is then 
postulated that keratinocytes, as a major cell type in epidermis, could be possibly activated 
by IL-33 and involved in IL-33-mediated skin inflammatory responses. Noting the 
evidence of tissue eosinophilia in AD and marked deposition of toxic eosinophil granule 
proteins in lesional skin of AD patients (K^p, 1993; Ott et d” 1994; Kiehl et oL, 2001; 
Simon et aL 2004), we explore the significance of IL-33 in eosinophil-keratinocyte 
interaction by coculturing human eosinophils and epidermal keratinocytes with IL-33 
stimulatioa 
Eosinophil recruitment from vascular compartment into inflamed skin tissue is a 
stepwise process involving sequential intercellular interactions of various adhesion 
molecules expressed on eosinophils and skin tissues (Rosenberg et o/. 2007). As 
keratinocytes from AD patients could produce elevated amount of chemokines including 
the eosinophil chemoattractant CCLll (Yawalkar et aL, 1999; Giustizieri et oL 2001; 
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Pastore et ai, 2006), eosinophils expressing chemokine receptors for a wide spectrum of 
chemokines could migrate towards epidermal keratinocytes along the chemokine gradient 
(Rothenbeig et al, 1999; Bnoide et oL, 2001). It has been reported that ICAM-1 is 
important for eosinophil trafficking by acting as binding sites for integrins, such as 
CDlla/18, CDlld/18, and CDllc/18, and fimctions as a signaling molecule, resulting in 
the activation of inflammatory signal cascades (Wardlaw, 2001; Rosenberg et oL, 2007; 
Smith, 2008). In addition, clustering of leukocyte integrins may drive inteigrin-mediated 
outside-in signaling responses and lead to firm cell adhesion, cell migration, as well as 
leukocyte activatioa It has been reported that this kind of signaling could stimulate T 
lymphocyte proliferation, IL-2 release, and stabilize T lymphocyte/antigen-presenting cell 
contacts; induce neutrophil degranulation and activate NADPH oxidase for reactive 
oxygen species generation; promote macrophage differentiation and IL-lp production 
(Abram et oL, 2009). The marked increase in CDl8 expression on human eosinophils and 
ICAM-1 expression on human epidermal keratinocytes in the co-culture system, as well as 
a fiirther profound elevation of these adhesion molecule expression induced by IL-33, may 
promote prominent direct interaction of eosinophils and keratinocytes for fiirther cellular 
activation, such as release of proinflammatory cytokines and chemokines, at the site of 
inflammation. 
We demonstrated that IL-33 could markedly activate both eosinophils and 
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keratinocytes cells to secrete proinflammatory cytokine IL-6 and chemokine CXCL8, 
while significantly stimulate eosinophils, but not keratinocytes, to release CCL2. Co-culture 
of eosinophils and epidermal keratinocytes could also augment the secretion of these 
pro-inflammatory cytokines and chemokines, which could be further enhanced by IL-33 
treatment With a view to identifying the source of cytokines and chemokines released in 
the co-culture system, a comparison of cytokine and chemokine concentrations in normal 
eosinophil-keratinocyte co-culture, and the co-culture of cells, either eosinophils or 
keratinoicytes fixed with 1% paraformaldehyde, was followed. Both eosinophils and 
keratinocytes cells are the main source for the proinflammatory cytokine and chemokine 
release in the co-culture system iqxm IL-33 stimulation. Furthermore, transwell insert 
separating eosinophils and keratinocytes into two compartments in the co-culture system 
could reduce the IL-33-mediated release of CCL2, but not CXCL8 and IL-6, in co-culture 
of IL-33 treated eosinophils and keratinocytes. The CCL2 release in the co-culture system 
may depend on direct interaction between eosinophils and epidermal keratinocytes; vsMe 
other soluble mediators derived specifically from IL-33 treated eosinophils or keratinocytes 
may be required for intercellular communication and induction of proinflammatory 
cytokine IL-6 and neutrophil chemokine CXCL8 release. 
Noting the fact that dermal proinflammatory infiltrate in AD includes a significant 
population of skin-homing CD45RO+ T lymphocytes expressing the selective skin-homing 
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receptor cutaneous-lymphocyte-associated antigen (Akdis et oL’ 2000), the profound 
increase in IL-33-mduced production ofIL-6 from eosinophil-keratinocyte interaction may 
enhance IL-2 receptor expression on these lymphocytes to promote their proliferation, and 
induce growth of epidermal keratinocytes (Naka et al” 2002), to sustain proinflammatory 
cytokine production in the inflamed skin tissues. In addition, prior study has revealed the 
significance ofIL-6 in mediating differentiation of Thl7 lymphocytes for the pathogenesis 
of inflammatory diseases (Acosta-Rodriguez et al., 2007). As Thl7 lymphocytes were 
shown to infiltrate in the acute lesional papillary dermis of AD (Koga et cd” 2008), 
IL-33-mduced IL-6 release from eosinophil-keratinocyte interaction may also provide a 
favourable microenvironment for Thl7 lymphocytes in driving skin inflammatory 
responses. 
It has been reported that iq>regulated expression of CCL2 was found in the epidermis 
of patients with AD (Giustizieri et al, 2001). Taken together with the studies on the roles of 
CCL2 in recruitment of monocytes, lymphocytes, and basophils; and induction of 
histamine and leukotriene release from mast cells and basophils (Conti et al, 1995; Rose et 
d., 2003), the significant IL-33-induced CCL2 release from eosinophil-keratinocyte 
interaction may facilitate the dermal infiltration of inflammatory leukocytes for promoting 
the development of allergic inflammation. As CXCL8 could potentiate neutrophil oxidative 
burst (Kobayashi et oL, 2008), the significant IL-33-induced CXCL8 release from 
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eosinophil-keratinocyte interaction may promote skin tissue destruction at the site of 
inflammatioa Noting the fact that keratinocytes of AD patients highly express CD4+ T 
lymphocyte chemoattractant IL-16, eosinophil chemoattractant CCLll, and eosinophil 
activator GM-CSF (Akdis et d.’ 2000; Pastore et al.’ 2006), the elevated production of 
these cytokines and chemokines may orchestrate with the IL-33-induced release of IL-6, 
CCL2, and CXCL8; and induce leukocytes migration and activation in the inflamed skin 
tissues. 
The epidermis is mainly comprised of epidermal keratinocytes (90-95%) with some 
non-keratinocytes like dendritic Langerfians cells, which could uptake exogenous antigens 
deposited on the skin, process and present them to naive skin-homing lymphocytes. It has 
been reported that the Langerfians cells could also interact and adhere with epidermal 
keratinocytes (Kanitakis, 2002). Among the BL-l femily cytokines, IL-18 could be 
produced by keratinocytes and Langerfians cells in the epidermis, and highly expressed in 
lesional skin of AD (Mttmann et oL’ 2009). Similar to IL-18, prior study shown that 
keratinocytes activated by proinflammatory cytokine EL-lp, and dendritic cells activated by 
lipopolysaccharide highly express IL-33 (Schmitz et al., 2005). The keratinocyte- and 
Langerhans cell-derived IL-33 may mediate skin inflammatory responses in microbial 
infection and allergic inflammation via the interaction between eosinophils and idermal 
keratinocytes (Figure 4.11). 
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Figure 4.11. Potential role of keratinocyte- and Langerhans celklerived IL-33 in 
mediating skm inflammatory responses in microbial infection and allelic 
inflammation 
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In conclusion, this is a first report on the role ofIL-33 in the interaction between human 
eosinophils and epidermal keratinocytes, with an initial focus on the aspects of modulation 
of surface adhesion molecule expression, and stimulation of cytokine and chemokine 
release. Taken together with previous reports on the potential participation of IL-33 in 
keratinocyte activation, this study provides further evidence of how IL-33 could be 
involved in the pathogenesis of AD. Further investigation of the underlying mechanisms 
may shed light on the development of novel treatment approaches for eosinophil-associated 
allergic diseases. 
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5.1 Concluding Remarks 
Eosinophilia and eosinophil activation are prominent in allelic diseases like allergic 
asthma and atopic dermatitis (AD) (Rosenberg et al., 2007; Simon et al., 2004). Noting 
the high expression of 11^33, the eleventh member of IL-1 family and a novel Th2 
cytokine, in human bronchial epithelial cells, and keratinocytes activated by 
proinflammatory cytokine IL-lp (Schmitz et al., 2005), we first investigated the 
activation of eosinophils induced by IL-33 and the underlying intracellular signaling 
mechanisms, with a comparison of the effects of two other IL-1 femily cytokines, IL-ip 
and IL-18. Furthermore, we explored the roles of IL-33 in eosinophil-keratinocyte 
interaction by co-culturing human eosinophils and epidermal keratinocytes with IL-33 
stimulation. 
Concurring with the evidence from recent studies (Cherry et al., 2008; Suzukawa et 
al., 2008) IL-33 could activate human eosinophils by mediating marked delay of 
eosinophil apoptosis. It could also induce significant enhancement of ICAM-1 
expression and down-regulation of ICAM-3 and L-selectin expression, as well as 
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prominent stimulation of proinflammatory cytokine IL-6 and chemokine CCL2 and 
CXCL8 release. Our study also confirmed the results of Pecaric-Petkovic's work (2009), 
which concurred that NF-KB, ERK and p38 M A P K pathways could be activated in 
eosinophils upon stimulation of 11^33, initiating the prolongation of eosinophil effector 
functions, migration, recmitment and activation of other inflammatory leukocytes for 
the development of allergic inflammation. 
The DL-l receptor/Toll-like receptor superfamily includes the receptors for IL-ip, 
EL-18 and IL-33, share a structural characteristic of ToU-IL-l receptor unit in their 
intracellular domain for signaling induction in inflammation and host defence (O'Neill 
et al.’ 2000; O'Neill et al., 2008). We demonstrated the importance of NF-KB ERK and 
p38 MAPK pathways in BL-ip- and IL-lS-mediated eosinophil activation, and revealed 
the sharing of these common signal transduction mechanisms among IL-lp, IL-18, and 
the novel IL-1 family cytokine IL-33 for driving proinflammatory responses. 
Noting the fact that both EL-lp and IL-6 were reported to promote differentiation 
of Thl7 lymphocytes, a novel IL-17-producmg Th lymphocyte subset, for facilitating 
leukocyte recruitment and inflammatory process in allergy (Acosta-Rodriguez et a/., 
2007; Schmidt-Weber et al., 2007), our study demonstrated the significant synergistic 
effects of IL-lp, IL-18, and IL-33 co-stimulation for induction of IL-6 release, which 
may further promote the pathogenesis of allergic inflammation via the paracrine 
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activation ofThlT lymphocytes. Furthermore, as IL-33 release is inducible in dendritic 
cells upon the activation by microbial lipopolysaccharide (Schmitz et al., 2005), 11^33 
could also orchestrate with DL l^p, 11^18 to induce IL-6 production and amplify 
inflammatory responses in microbial infection. 
The complex interaction between resident structural cells and eosinophils has been 
postulated as a fundamental mechanism directing the progression of allergic 
inflammation (Wong et oL, 2006). In addition, tissue eosinophilia and significant 
extracellular deposition of eosinophil granule protein lesional skin of AD patients were 
found in AD patients (Kapp et al., 1993; Simon et al, 2004). In our co-culture system, 
IL-33 could mediate marked activation and interaction between human eosinophils and 
epidermal keratinocytes. The significant elevation of CD 18 expression on human 
eosinophils and ICAM-1 expression on human epidermal keratinocytes in the 
IL-33-stiinulated co-culture system may facilitate direct interaction of eosinophils and 
keratinocytes at the site of inflammation. Profound induction of proinflammatory 
cytokine and chemokine release in IL-33-stimulated eosinophil-keratinocyte coculture 
may favour infiltration of proinflammatory leukocytes and fiuther activation of resident 
cells ill the AD lesional skill, promoting the pathogenesis of allergic skin inflammation. 
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5.2 Future Perspectives 
Noting the fact that fibroblasts are fiindamental resident cells in dermis, a 
connective tissue beneath the epidermis (Kanitakis, 2002), eosinophils migrating 
towards the upper lesion of the skins along the chemoldne gradient may interact with 
dermal fibroblasts first in AD, shortly after their endothelial transmigration. Prior study 
demonstrated that dermal fibroblasts activated bylL-ip and TNF-a express significantly 
more IL-33 than keratinocytes activated by the same stimuli (Schmitz et a/.’ 2005), 
suggesting a potential role of IL-33 in activation of dermal fibroblasts and 
eosinophil-fibroblast interaction in the inflamed dermis. Comparative study of the 
IL-33-mediated eosinophil-dermal fibroblast and eosinophil-epidermal keratinocytes 
interaction may provide more clues on the IL-33-incluced sequential activation of 
eosinophils and structural cells in the lesional skin of AD. 
As IL-33 could induce profound pathological changes including bronchoalveolar 
lavage fluid eosinophilia, airway hyperresponsiveness, as well as epithelial cell 
hyperplasia and hypertrophy in airway of mouse model (Schmitz et al., 2005; Kondo et 
al.’ 2008; Kurowska-Stolarska et al., 2008), this should support further elucidation of 
direct and indirect effects of bronchial epithelial cell-derived IL-33 in asthmatic airway 
(Schmitz a/ , 2005). 
Soluble ST2, highly expressed in asthmatic exacerbation (Oshikawa et al., 2001), 
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could attenuate eosinophil infiltration and Th2 cytokine production in asthmatic murine 
model (Oshikawa et ai, 2002; Hayakawa et al., 2007), though the induction and 
functions of soluble ST2 are not M y understood. Further investigation of multiple roles 
ofIL-33 in activation of leukocytes and resident structural cells, as well as the regulating 
mechanisms may improve our understanding of the immunological basis of allergic 
diseases. With the insight from the development of new biologic agents including IL-1 
receptor antagonist anakinra and anti-IL-6 receptor monoclonal antibody tocilizumab 
for rheumatoid arthritis (Gibbons et oL, 2009), the use of anti-ST2 and recombinant ST2 
proteins as new therapeutic strategy for allergic diseases could be fiirther explored. 
Innovating more new generations of signaling inhibitors based on their core 
chemical structures and substitution of functional groups, there are mounting patent 
applications filed by a number of pharmaceutical corporations. Despite this, the 
specificity, efficacy, and potential adverse impacts of these inhibitors in human are still 
under investigation in phase I and phase H clinical trials (Cirillo et ai, 2002; Dominguez 
et al., 2005). Extensive work revealing the compound specificity and efficacy, and the 
regulatory issues is pivotal for the launch of these compounds approved for therapeutic 
use in allergy. 
RNA interference or RNA silencing is another potential therapeutic approach that 
use 21-23 nucleotide small interfering RNA (siRNA) to potently and selectively 
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suppress post-transcriptional expression of gene expression, including that of cell 
surface receptors and cytokines, in human cells (Popescu, 2005). The anti-inflammatory 
effects of siRNA application were demonstrated in both in vitro studies and mouse 
asthma model (Taka et cd., 2008; Suzuki et al, 2009). It is postulated that respirable 
siRNAs could be effective at doses that are lower than other routes of administration 
due to the direct delivery as aerosols to inflamed lung tissues. Studies on how specific 
siRNAs at low but efficacious doses could be safety delivered to the target tissues may 
help exploration and identification of new clinical management of allergy. Further 
investigation and development of more effective and specific inhibitors should advance 
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